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CHAPTER I
INTRODUCTION AND REVIEW OF RELATED LITERATURE
Research interest has recently developed for a
group of chemical compounds which have immunomodulatory
properties.

These compounds exert anti-microbial actions

which have been termed "prohost"

(20) because, rather

than being directly bactericidal or fungicidal, they
either restore the host's deficient immune response or
augment a normal response.

Under specified conditions,

these drugs could become highly important in treating
immunodeficiency diseases, as well as viral, fungal, and
bacterial infections.

With the increasingly frequent

development of single and multiple resistance to conventional antibiotic therapy (4,6,10,21), immunopotentiators
become increasingly more important therapeutic alternatives.

Also, in therapy for atopic individuals who

experience undesirable side effects from traditional
treatment (1,27,61), or in cases where adverse effects
such as oto- or nephrotoxicity accompany the use of antibiotics (5,11), immunomodulators may provide successful
treatment with fewer serious complications as a result
of therapy.

1
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Immunomodulatory substances consist of a wide
variety of agents including micro-organisms and their
subcellular fractions

(mycobacteria, Corynebacterium

parvuurn, LPS, zymosan), macromolecules such as nucleic
acids or polynucleotides, small inorganic or organic
molecules (silica, alum, fatty acids), or pharmacologic
agents such as levamisole (1,2,3,5 tetrahydro-6-phenylamidazo (2,1-S)-thiazol, monohydrochloride).
effect their actions in a number of ways:

These agents

by prolonging

antigen release, by recruitment of macrophages and lymphocytes, by stimulating proliferation and differentiation
of immunologically competent cells or by the enhancement
of cellularly mediated immune responses (64).
Since complex immune mechanisms are affected by
such immunomodulation, it could be expected that specific
drug regimens may be more effective when immune cells are
most sensitive to regulation.

This has been demonstrated

to occur in levamisole therapy where pre-infection drug
treatment was effective against a bacterial agent (12)
while simultaneous or post-infection therapy was ineffective.

In particular, synthetic, non-polymer pharmacologic

agents have been found to enhance the cellular immune
response.

A principle action of these agents involves

the potentiation of the thymus-derived T-lymphocytes and
the proliferation and/or activation of the monocytederived tissue macrophage (20).

3

One such immunomodulatory agent is SM-1213 (1,2-0isopropylidene-3-0-3'-(N',N'-dimethylamino-n-propyl)-Dglucofuranose), a synthetic, substituted monosaccharide.
The possible enhancement of host defenses by such a drug
during active infection has prompted a careful examination
of the in vitro and in vivo effects of this substance.
Recent studies have elucidated the anti-viral or
immunomodulatory properties of SM-1213 in rhinovirus (15,
16), influenza and vaccinia viruses (17), and in herpes
simplex virus infections in mice (39) and hamsters (18).
Oral SM-1213 therapy has been demonstrated to delay death
in Bl6 melanoma-bearing C57BL mice, as well as enhance
delayed-type immune responses in Ha/ICR mice challenged
with human type 0 red blood cells (38).

In addition,

SM-1213 has been shown to significantly increase intracellular killing of bacteria (20) in studies concerning
infection of a macrophage monolayer with Listeria monocytogenes.

No studies, however, have examined the effects

of SM-1213 upon in vitro or in vivo fungal infection.
Candida albicans is a fungus commonly found as part
of the normal flora of many mammals, including man.

It is

considered an opportunistic fungus, since individuals who
carry the organism do not display symptoms of infection
unless injury or metabolic disorders reduce resistance
to microbial invasion.

Diabetes, indwelling catheters,

and broad-spectrum antibiotic or immunosuppressive therapy
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are all factors which favor the development of candidiasis.
In addition, patients with various neoplasms, immunological defects, or serious burns are highly susceptible to
candidal infection (48).
The wide range of factors contributing to susceptibility to candidiasis, the poor and even damaging chemotherapy available, and the increased incidence of systemic
disease (22) have made candidiasis a serious clinical
problem.

Therefore, studies of the causative organism

were undertaken to examine the mechanisms of pathogenesis
and immunity in candidiasis and the effects of SM-1213
therapy on host defense.
A.

In Vitro Studies
Several researchers have examined the ability of

polymorphonuclear leukocytes (PMN) or macrophages to
phagocytize and kill intracellular Candida albicans (2,
36,60,63).

In general, the PMN leukocyte has been demon-

strated to be more efficient in destroying Candida than
the macrophage (2).
Stanley and Hurley (60) observed that cultured
mouse peritoneal macrophages were destroyed by the elongation of candidal germ tubes and that escaping Candida
survived ingestion.

In addition, Lauria and Brayton (37)

suggested that the pathogenicity of various strains of
Candida albicans in mice is roughly correlated to the
ability of Candida to form germ tubes and survive ingestion
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by leukocytes derived from human blood.

These studies

demonstrate the invasiveness of Candida to be related to
the hyphal rather than to the yeast form of this microorganism.
Lehrer and Cline (36), however, have shown that a
significant fraction of Candida phagocytized by PMN's in
vitro are destroyed.

Arai et al (2) also found the guinea

pig peritoneal neutrophil capable of killing intracellular
Candida in the presence of normal serum.

Rabbit alveolar

macrophages, on the other hand, whether in the presence of
normal or immune serum, showed no Candida dead after one
hour of incubation.

No significant improvement of candi-

dacidal activity was observed when macrophages derived
from immune or normal rabbits were exposed to immune serum,
but an enhancement of phagocytic ability of these cells
was evident.
opsonization.

It was suggested that immune serum enhanced
However, Venkataraman et al (63), working

with immune rabbit neutrophils, demonstrated no significant
enhancement of phagocytosis, but rather an enhancement of
candidacidal properties in combination with immune serum.
Studies were therefore conducted in our laboratory
to determine whether glycogen induced guinea pig peritoneal neutrophils and paraffin oil induced peritoneal
macrophages could inhibit intracellular Candida in vitro
with or without the addition of whole, normal guinea pig
serum.
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B.

In Vivo Studies

1.

Intravenous Inoculations
Conventional therapy for a systemic candidal in-

fection involves the use of a polyene antifungal agent
such as amphotericin B.

While being relatively effective

in the treatment of such infections, amphotericin B has
concomitant deleterious side effects, particularly renal
damage (62).

Since the kidney has also been demonstrated

to be a primary organ damaged in systemic candidiasis (26,
37,51,66), treatment of these patients with amphotericin
B may compound the problem.

In addition, individuals

receiving immunosuppressive cortisone therapy often become infected with Candida (13) and are subsequently
treated with amphotericin B; recent evidence indicates
that amphotericin B can be synergistically nephrotoxic
in mice receiving cortisone therapy (30).
Unlike amphotericin B, SM-1213 is a drug of low
toxicity.

The acute oral LDso of SM-1213 in mice (17),

rats, and rhesus monkeys has been determined to be greater
than 10 g/kg, or greater than 10 4 the usual therapeutic
dose.

In tissue culture studies, anti-viral and anti-

bacterial effects were demonstrated while toxicity to
tissue culture cells was not evident at SM-1213 concentrations 1000 times higher than the effective dosage
(17,20).
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In addition, unlike other immunomodulatory substances (12),

8~1-1213

does not require administration

prior to infection (15,17,39).

This aspect of SM-1213

treatment could therefore prove useful in the therapy of
disease states upon the appearance of symptoms (38).
Therefore, if SM-1213 could be proven to be effective
against a systemic candidal infection, it might provide
a viable alternative to classical polyene antibiotic
therapy.
The pathogenesis of systemic candidal infection
has been examined by several researchers; the kidney has
been demonstrated to be a primary organ damaged by such
infection.
Hurley and Winner (26) described an acute and a
chronic type of kidney involvement in Swiss mice infected
intravenously with 1.5 X 10 4 to 4 X 10 6 candidal cells.
Doses of 2 X 10 6 or more candidal cells per mouse caused
animals to develop acute diseases and to succumb within
one to ten days with histologically distinct lesions in
the heart, brain, and kidneys.

Chronic kidney disease

occurred in mice dying in six to sixty days with lesions
confined to the kidneys.
In a similar study, Winbald (66) also showed that
the kidney was an organ of major involvement.

In mice

infected with 8 X 10 4 Candida cells intravenously, histology and scanning electron microscopy of the infected
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kidneys demonstrated two types of involvement:

acute

(occurring within ten days of challenge) and chronic
(occurring in those mice surviving longer than ten days
post-infection) .
Studies conducted by Rogers and Balish (50) on
clearance of Candida from liver, lungs, kidneys, and
spleens of male Swiss-Webster mice infected with various
doses of Candida intravenously have shown that 60-120
minutes after injection, the kidney, on a weight basis,
was the most efficient organ for clearing Candida from
the bloodstream.

The kidneys became chronically infected

17-24 days post-challenge with 1-3 X 10 4 viable units of
Candida injected.

Increasing numbers of Candida were

found in the kidneys and, by day 24 post-infection, the
number of viable units was as high as 1 X 10 6 per two
kidneys.
Louria and Brayton (37) studied Swiss mice infected
intravenously with various strains and inocula of Candida.
Tissue homogenates were performed on kidney, spleen,
liver, heart, brain, and lung tissues after intravenous
challenge with 1 X 10 5 Candida cells of the PR strain.
Progressive infection occurred only in the kidneys by
day 7 post-infection.

Populations in brain, heart, liver,

spleen, and lung samples remained unchanged or fell by
day 7, while that of the kidney increased.

The authors

suggested such an increase was related to a four hour
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delay in mobilization of neutrophils to this organ and
that, once Candida were able to germinate within the kidney
tubule lumens, they were able to evade the host's inflammatory response.
2.

Intramuscular Inoculations
Mice injected intravenously with Candida albicans

frequently succumb to infection within two weeks, which
hinders the study of the course of an immune response.
By using a model developed by Selbie and O'Grady (57) and
modified by Pearsall and Lagunoff (44), it became possible
to study the mechanisms of candidal pathogenesis and
immunity in mice under the influence of drug therapy.
Selbie and O'Grady (57) developed a model whereby
mice were injected intramuscularly in the thigh so as to
produce a measurable tuberculous lesion.

Pearsall and

Lagunoff (44) used such a model to examine experimental
candidiasis in mice.

An inoculum of 5 X 10 8 Candida cells

was injected into the thigh muscle of C57BL/Ks mice and
the development of candidal abscesses was monitored by
periodic measurement of the infected leg with the aid of
a caliper.

Histological examination revealed a predom-

inantly granulocytic infiltrate of cells.

Lesions were

self-limiting within four to six weeks post-infection.
Immunity to abscess formation could be passively
transferred by the use of immune serum, but not by the
administration of lymphoid cells obtained from convalescing
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mice ( 43) .
Secondary leg inoculations of Candida into the
uninfected contralateral leg of recovered mice were also
conducted by Pearsall and Lagunoff (43).

Such inocula-

tions were used by Pearsall and Lagunoff to determine the
acquisition of immunity to abscess formation following an
initial infection.
While Pearsall and Lagunoff (44) examined the
histology of the leg lesions, no culturing of the abscesses
or visceral organs was conducted.
C.

Purpose of the Present Work
The purpose of this thesis is to examine the pos-

sible enhancement of host defenses by SM-1213 during an
infection produced by experimental injection of Candida
albicans.

Initially, in order to determine whether or not

there is a direct fungicidal or fungistatic activity associated with SM-1213 treatment, an examination of the effect
of SM-1213 concentration on the growth of the yeast and
hyphal forms of Candida albicans will be undertaken.

In

addition, an examination of the effect of SM-1213 concentration upon leukocytes infected in vitro with C. albicans
will be discussed.

In particular, SM-1213 treatment will

be investigated for its effect on the ability of peritoneal
exudate cells in tissue culture to inhibit intracellular
germ tube elongation and to reduce candidal viability.
The effect of whole, normal guinea pig serum on germ tube
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elongation and candidal viability within phagocytic leukocytes in the presence and absence of SM-1213 will also be
examined.
In vivo, studies will be conducted to examine the
effects of oral SM-1213 drug therapy upon systemic infection in mice injected intravenously with C. albicans.
Since host defense mechanisms evolve during the interval
following the initiation of infection, and since immunemodulatory substances may prove most effective when host
defense mechanisms are sensitive to regulation (12),
various regimens of drug treatment will be tested.

In

addition, since the kidney is a primary organ in the pathogenesis of candidiasis (26,66), tissue homogenizations
of kidneys from intravenously infected mice will be performed to assess renal involvement in control and drug
treated mice.
The effects of SM-1213 treatment on the course of
leg lesion development in intramuscularly infected mice
will also be investigated.

Leg lesion development will

be monitored periodically with the aid of adjustable
calipers and leg swelling will be used as an indicator of
the pathogenesis of candidal disease.

Recovered mice will

be reinoculated in the contralateral leg to assess the
effect of SM-1213 on lesion development during a second
infection when drug is administered during initial infection only.

Also, leg lesions will be cultured or homo-
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genized to detect the presence of C. albicans and kidneys
and/or spleens of intramuscularly infected mice will be
examined for the metastatic spread of fungus.

It is hypo-

thesized that SM-1213, via its irnrnunomodulatory properties,
will promote the fungistatic or fungicidal capabilities of
leukocytes in vitro and will promote an enhanced host
defense in vivo against experimentally induced infections
of Candida albicans.

CHAPTER II
MATERIALS AND METHODS
A.

Experimental Drug
SM-1213 (1,2-0-isopropylidene-3-0-3'-(N',N'-di-

methylamino-n-propyl)-D-glucofuranose, monohydrochloride)
was supplied by Dr. Paul Gordon, Greenwich Pharmaceuticals,
Inc., Greenwich, CT. and Department of Microbiology,
Loyola University, Stritch School of Medicine, Maywood, IL.
The chemical structure of the drug is represented in
Figure 1.

SM-1213, lot #13/24-31, hydrated from the

powdered form with distilled water, was stored at -20°C
in 5 ml stock solutions (50 mg/100 ml) and diluted as
needed.
B.

Micro-organism
Candida albicans originally isolated from a human

patient was kindly supplied by Dr. T. Hashimoto of this
department.

Permanent stocks were lyophilized in Sabour-

aud's dextrose broth (Difco) and rehydrated as needed.
Working stocks were kept on Sabouraud's dextrose agar
(Difco) slants at room temperature and at 4°C and transferred at monthly intervals.
This strain showed typical features of Candida
albicans when tested in a Uni-Yeast-Tek diagnostic system
13

14

Figure 1. The chemical structure of SM-1213 (1,2-0isopropylidene-3-0-3'-(N', N'-dimethylamino-n-propyl)-D-glucofuranose, monohydrochloride).

15

HO- CH2

I
HO-CH

0
H

H

C-CH

/1
H

0

SM-1213

CH3

3

16
(Corning Medical Microbiology, Roslyn, NY).

Assimilation

of sucrose and maltose with latent assimilation of trehalose and soluble starch and lack of lactose, raffinose,
and cellobiose utilization as well as negative urea and
nitrate tests were identifying characteristics.

In addi-

tion, characteristic germ tube formation in the presence
of serum, characteristic filamentous growth on EMB agar,
and typical chlamydospore formation on corn meal-tween
agar were confirmatory.
Cultures used for injection were grown for 24 to
72 hours at 37°C on Sabouraud's dextrose agar (SDA) or in
Sabouraud's dextrose broth (SDB)

to which 50

~g

gentamicin/

ml (Garamycin, Schering Pharmaceutical Corp., P.R.) had
been added to retard bacterial growth.
Final suspensions of Candida to be used for injection were made in sterile Na-K phosphate buffered saline
(PBS, pH 7.3, % w/v in distilled water: NaCl 0.8, KCl 0.02,
KH 2 P0 4 0.012, and Na 2 HP0 4 0.091).

Candida were quantified

prior to infection in a hemocytometer (Bright-Line, American Optical Co.) and serially diluted and plated on SDA
for the determination of colony forming units.
Day 1 has been designated as the day of infection
in all of the following experiments.
C.

Experimental Animals
Intravenous inoculations were carried out in male,
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randomly-bred, Ha/ICR mice (Sprague-Dawley, division of
Mogul Corp., Madison, Wise.).

Several strains of mice

were tested for use in leg inoculation studies (Ha/ICR,
C3H, Balb/c, and CBA/J).

The CBA/J strain of mouse was

determined to be most suitable for these studies for
reasons which will be detailed later.

CBA/J mice were

numbered by ear punch and randomized for each experiment.
Ha/ICR mice were numbered with 0.1% w/v picric acidethanol dye and randomized for each experiment.

Mice

were primarily 4 to 6 week old males, weighing 20 to 25
grams at the time of experimental initiation.
Mice were fed (Purina Rat Chow #5012) and watered
ad libitum.

Animals were housed at this laboratory's

isolation facility (Building 188) in plastic cages in
groups of 5 to 10 per cage.

Twelve hour diurnal rhythms

were maintained with automatically timed lighting.

Tem-

peratures were controlled to comfortably maintain the
animals at 22-24°C.
Male guinea pigs, Hartley strain, weighing approximately 500 grams, were housed on the second floor of the
Stritch School of Medicine in metal cages in groups of
three.

The guinea pigs were fed (Purina Guinea Pig Chow)

and watered ad libitum.

Guinea pigs were used for peri-

toneal exudate cell harvests, since sufficient numbers of
leukocytes could be obtained from one animal for each
experiment.
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D.

Drug Administration
Drug was administered ad libitum in the drinking

water of animals receiving therapy.

Water consumption of

drug treated animals was similar to control animals receiving water without an additive.

Drug concentrations

were prepared so as to allow the desired consumption over
each 24-hour interval based on the observed drinking
habits of the experimental animals.

Thus, for normal

mice early in infection, 4 ml of water was consumed per
day per mouse.
gavage.

Alternatively, drug was administered by

Gavage doses were administered according to the

average cage weight and were given as

~g/kg/day.

Stain-

less steel gavage tubes (Popper and Sons, Inc., New Hyde
Park, NY) were placed on 1 ml tuberculin syringes (BectonDickinson and Co., NJ) and drug was thereby given orally
by placement of the tube into the esophagus.
E.

Statistical Analysis
In mortality studies, tissue homogenization studies,

and viability studies, the

x2

analysis was used; for germ

tube elongation averages and average animal weight and
abscess sizes, the Student's t test was utilized.
Pearson's r was used to determine correlations.

The
Averages

were represented plus or minus (±) the standard error of
the mean.

P values were considered significant when they

were less than 0.05.
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F.

In Vitro Studies

1.

Methods for Determining the Effects of SM-1213 on the
Growth of Candida albicans
In order to determine whether SM-1213 had direct

inhibitory effects on the growth of Candida, 100 ml of
Sabouraud's dextrose broth (SDB) in 500 ml side-arm Erlenmeyer flasks were inoculated with 1 X 10 5 Candida cells.
Candida had been grown for 24 hours on SDA at 37°C prior
to inoculation.

The increase in turbidity in each of

five flasks with different concentrations of SM-1213 were
monitored.

Concentrations of SM-1213 tested were:

(Control), 1.0, 0.1, 0.01, and 0.001

~g/ml.

0

Also, a con-

trol blank (no drug, no Candida) was examined.

Hourly

turbiometric readings were taken at 660 nm on a Bausch
and Lomb Spectronic 70 spectrophotometer over a period of
ten hours.

Since greater than 98% of Candida grew in the

yeast form in SDB, such readings demonstrated what effect,
if any, SM-1213 had on this morphologic form of Candida.
The normal growth of this particular strain of Candida
albicans in SDB was also determined from this data.
To determine whether SM-1213 had a direct effect
upon the hyphal form of Candida, 250 ml flasks containing
50 ml of HI-W05/BA2ooo tissue culture medium with the
above concentrations of SM-1213 were inoculated with 10 5
Candida cells and incubated for 24 hours on a rotary shaker
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at 37°C.

The growth was determined in each of these

flasks by dry weight analysis.

Dry weight determinations

were made after Millipore filtration of the cultures.
Three washes of the Candida were performed with distilled
water while on the filtration system, followed by drying
of the filters in a Stabil-Therm oven (Model #OV-12) at
60°C for 48 hours.
2.

Methods for Peritoneal Cell Harvest, Infection add
Tissue Culture
One white guinea pig (Hartley strain, male, 500 g)

was used in each of the in vitro experiments as a source
of peritoneal exudate cells.

Either 20 ml of paraffin

oil (mineral oil) or glycogen (0.1% w/v in Earle's balanced salt solution) was used as an inducing agent.
Harvesting procedures were identical for both types of
inducing agents except that the paraffin oil was injected
into the peritoneal cavity 72 hours prior to animal sacrifice while the glycogen was injected 24 hours prior to
sacrifice.

The abdomen of the guinea pig was shaved with

an electric shaver (Oster) and cleansed with 70% isopropyl
alcohol (Alco-Wipes, Will Ross, Inc., Milwaukee, WI) prior
to injection of the inducing agent.
On the day of sacrifice, peritoneal cells were
harvested from the guinea pig by five serial washes of
20 ml volumes of heparinized Eagle's basal medium (BME)
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containing 50

~g

gentamicin/ml.

Five units of heparin/ml

was included in the medium to inhibit aggregation of exudate cells.

A 20 ml plastic syringe and 19 gauge needle

was used to deliver the BME into the peritoneum for each
wash.

Cell harvests were facilitated by a 5 em longitu-

dinal incision in the abdominal wall to allow access to
the peritoneum.

A 5 ml polystyrene disposable pipet

(Scientific Products, Division of American Hospital Supply)
could then be used to collect the wash fluid from the
cavity.

Polystyrene equipment was used to lessen the ad-

herence and subsequent loss of peritoneal cells during
harvesting procedures.

The washes were delivered into

sterile, 40 ml screw-cap plastic centrifuge tubes and the
cells were pelleted by centrifugation at 250 X G for 5
minutes (20°C) in an International PR-6 centrifuge.

The

pellet was resuspended and washed three times in HI-W0 5 /
BA 2000 serum-free medium (International Scientific).
After washing, the cells were counted in a hemocytometer (Bright-Line, American Optical).

A total leuko-

cyte count was made and a differential count was then
performed on Wright-Giemsa (Harleco, Division of American
Hospital Supply) stained smears.
Total harvests ranged from 5.8 X 10 7 cells from
paraffin oil induction (65% macrophages) to 1.1 X 10 7
cells from glycogen induction (54% polymorphonuclear cells;
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remainder rnacrophages, rnonocytes, and lymphocytes).

Cells

were then seeded onto 60 rnrn plastic tissue culture Petri
plates containing two 2.2 ern square glass cover slips (#1
thickness) .

It was found that the most workable number

of cells was 2 X 10 6 per Petri plate.

These cells were

then incubated in HI-vv0 5 /BA2ooo medium with or without the
addition of SM-1213 for two hours at 37°C, 5% C02 atmosphere, to allow attachment of the cells to the cover slips.
Concentrations of SM-1213 tested were 0.1, 0.01, 0.001,
and 0.0

(control)

~g/rnl.

In cell cultures containing 2 X 10 6 peritoneal
cells per plate, 2 to 4 X 10 5 Candida cells were inoculated into the culture medium directly following the addition of peritoneal cells.

After two hours, non-adherent

cells were removed by washing once with HI-W0 5 /BA 2000
medium and appropriate medium (with or without SM-1213)
was replaced for those samples requiring further incubation.

In this way, any extracellular Candida was removed

after the initial two hours of incubation by the medium
wash described above.

A Candida to peritoneal cell ratio

of 1:5 to 1:10 permitted ideal measurements, since only
one Candida would be contained in any one peritoneal cell.
In studies employing serum, whole normal guinea pig serum
obtained from cardiac puncture and stored frozen at -20°C
was added to each sample to a final concentration of 2%
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v/v.

Serum was added to the cultures following the addi-

tion of cells.
Candida albicans was grown on Sabouraud's dextrose
agar for 24 hours at 37°C.

Under these conditions,

greater than 95% of the Candida cells were in the yeast
phase.

Suspensions of Candida were made in phosphate

buffered saline (PBS, pH 7.3).

A Klett colorimeter

reading (Filter #66) of 100 was determined by colony
count enumeration to be equivalent to 1 X 10 7 Candida
cells/ml.
a.

Determination of Candidal Germ Tube Elongation
At intervals of 2, 4, and 6 hours, one cover slip

was removed from the Petri plate and placed in a staining
dish containing 95% methanol for 5 minutes.

Such treat-

ment caused the cells to become fixed and allowed for
microscopic examination.

Upon removal from the methanol

bath, the cover slip was air dried and inverted onto a
drop of distilled water on a glass microscope slide.

The

peritoneal cells on the cover slip were then examined by
phase contrast microscopy at lOOOX for intracellular germ
tube elongation.

The germ tube lengths of Candida con-

tained in 50 peritoneal cells were determined through the
use of a micrometer in the eyepiece of the microscope.
Intracellular germ tube elongation was monitored at the
2, 4, and 6 hour intervals in this manner.
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b.

Determination of Candidal Viability
The second, remaining cover slip was removed from

the Petri plate with forceps and rinsed in successive
baths of PBS and SDB.

Such baths were instituted to

remove any residual tissue culture medium from the cover
slip.

Candida develop hyphae in tissue culture medium

and the yeast form, which develops on SDA, was required
for this section of the assay.

(Viability of Candida was

determined by their ability to grow out of peritoneal
cells via hyphae and form colonies of yeast on SDA.
Morphology was therefore highly important in this assay.)
I

Washed cover slips were then drained by touching one
corner of the cover slip to a piece of filter paper.

The

cover slip was then inverted onto a Petri plate containing
1

a thin layer (3 mm) of SDA and incubated for
37°C (normal atmosphere) .

2~

hours at

If not properly drained, air

would be occluded between the cover slip and the agar
and hyphae would develop.

After incubation, the Petri

plates were refrigerated overnight at 4°C and examined
microscopically at lOOOX the next day for Candida colony
formation.

Four adjacent yeast cells were designated as

one colony unit.

The percentage of viable Candida cells

could then be determined by counting 100 peritoneal cells
~hich

contained Candida:
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Number of Candida forming colonies
% Viable
100
Number of Candida X
= cells
Number of Candida + unable to form
forming colonies
colonies
G.

In Vivo Studies

1.

Intravenous Inoculations
The object of this series of studies was to deter-

mine the effects of SM-1213 treatment on the survival
rate of mice with experimentally induced systemic infections of Candida albicans.

In particular, the effects of

various regimens of drug therapy were investigated.
a.

Computation of the 50% Lethal Dose (LD 50

)

The method of Reed and Muench (47) was used to
determine the LDso for the strain of Candida albicans
used in the following experiments.

Candida doses used

for these calculations were 10 8 , 1.5 X 10 7

,

10 6

,

and 10 5

per animal injected intravenously into the left lateral
tail vein of male, Ha/ICR mice; a 26-gauge needle and a
1 ml tuberculin syringe were utilized.

Candida were sus-

pended in sterile PBS and 0.1 ml volumes were injected.
b.

Methods for Mouse Mortality Studies
Yeast cell suspensions of Candida albicans were

made in PBS and counted in a hemocytometer.
grown for 48 hours on SDA at 37°C.

Candida were

Viability of candidal

suspensions was determined by plating serial dilutions
by the spread plate method and counting colony formation
48 hours later.
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Male, Ha/ICR mice were injected with 2 X 10 5
Candida cells in the lateral tail vein with a 26-gauge
needle and 1 ml tuberculin syringe; volumes injected were
0.1 ml per mouse.
SM-1213 was administered ad libitum in the drinking water of test animals for various 24-hour intervals
only.

A dosage of 80

~g/kg/day

was administered for 24

hours only either beginning on the day of infection
(immediately following infection and designated as day
1-2 treatment), or beginning one, two, or three days
following infection (designated as day 2-3, day 3-4, and
day 4-5 treatment, respectively).
2.

Intramuscular Inoculations
In primary leg inoculations, male, CBA/J mice were

injected into the right lateral calf muscle with either
7 X 10 6

,

1.25 X 10 7

,

or 1.25 X 10 8 Candida cells per

mouse, depending upon experimental design.

The left leg

served as a control for daily measurements, as did uninfected control animals injected with PBS only in the right
leg.

The diameter (lateral to medial) of the uninfected

left leg of each mouse was subtracted from the diameter
of the infected right leg to determine the size of the
abscess produced.

Such methods were undertaken to allow

for any increases in leg diameter due to growth of the
animal which would occur bilaterally.

Corrections for
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original differences between the right and left leg were
made by measuring both legs before infection, determining
the difference, and subtracting this original difference
from the post-infection difference for each animal for
each measurement day.

Such corrections did not signifi-

cantly alter the average abscess size of any experimental
group; however, corrections were made to determine the
more precise abscess size for each animal before averages
were calculated.

The phrase ''abscess size" has been used

interchangeably with the phrase ''leg swelling."

The

latter is the more correct expression of leg measurement
data.
Injections were made with a 27-gauge needle and 1
ml tuberculin syringe.

Leg swelling was measured mechan-

ically in mm using a Schnelltaster numerical dial caliper
(H. Kroplein, Hassen, W. Germany).

Care was taken to

extend the leg thoroughly when measurements were taken.
Secondary leg inoculations in mice which had recovered from a primary leg infection were performed on
the uninfected contralateral leg with 1 X 10 5 Candida
cells intramuscularly.

No further administration of drug

was used beyond that given during the primary infection.
Re-inoculation was performed on day 57 of the primary
infection; therefore, the long-term effects of SM-1213
treatment given during the initial infection were examined during a second infection.
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a.

Tissue Homogenization Techniques
In order to obtain a quantitative measurement of

candidal infection, tissue homogenization studies were
undertaken.

Spleens, abscesses, and/or kidneys were

removed aseptically and placed into sterile vials containing 2 to 5 ml of PBS.

Tissues were homogenized in

this solution with Duall 24 ground glass tissue homogenizer tubes and pestles

(Kontes Glass Co.)

A Tri-R Stir-R

(50 to 1100 variable rpm, model K-43) motor was used at
setting #7.

After homogenization, tubes and pestles were

rinsed with 3 to 5 ml of PBS whichwere then added to the
tissue homogenate.
of kidneys

was

Each spleen, abscess, and each pair

homogenized separately.

Abscesses were

obtained by excising the abscess and all surrounding
muscle tissue located between the knee and ankle joint
with sterile surgical scissors.
Quantitation of viable Candida was obtained by
serial dilution of the tissue homogenates and spread
plate enumeration.

Three dilutions of each sample were

plated in duplicate (10- 1

,

10- 3

,

and 10- 5 ) and colony

counts were performed on 48-hour cultures incubated at
37°C.
b.

Culturing Techniques
At the time of sacrifice, animals were killed by

cervical dislocation and the right leg was skinned and
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removed aseptically by cutting with surgical scissors
transversely through the femur and the ankle.

This por-

tion of the leg, containing the abscess, was placed into
25 ml sterile, cotton-plugged Erlenmeyer flasks containing
10 ml of SDB + gentamicin (Gm) .

The specimen was minced

50 times with surgical scissors which had been flame
sterilized with ethanol.

Flasks were then placed in a

shaking water bath incubator (Warner-Chilcott Laboratories,
Morris Plains, NJ) at 37°C for 24 hours.

Colony count

enumerations were carried out on serial dilutions of the
tissue suspension plated out on SDA and incubated for 48
hours at 37°C.

Similarly, each pair of kidneys and each

spleen was aseptically removed and cultured in the same
manner following mincing.

Such a technique was developed

so that qualitative differences could be determined between samples.

This was particularly importantin detecting

small quantities of micro-organisms which may not have been
detected using classical tissue homogenization techniques.
c.

Weight Gain Determinations
In weight gain studies, correction for abscess

weight was determined by subtracting the weight of a
sphere from the animal weight.

The volume of the sphere

was determined by using one-half the abscess size as the
radius in the equation V = jnr 3

•

The density was desig-

nated as approximately equal to 1 g/ml and the mass could
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thereby be determined mathematically (mass

=

density X

volume) and subtracted from the animal weight.

CHAPTER III
RESULTS
A.

In Vitro Studies

1.

Effects of SM-1213 on the Growth of Candida albicans
As shown in Tables 1 and 2, SM-1213 had no direct

fungicidal or fungistatic activity against Candida when
tested in Sabouraud's dextrose broth (yeast form of
Candida) or HI-WOs/BAzooo tissue culture medium (hyphal
form of Candida).

Turbidity was virtually identical in

all samples tested regardless of drug concentration (see
Table 1) .

The higher turbidometric reading obtained for

the control sample at the 5 hour interval was attributed
to a procedural artifact resulting from insufficient
shaking of the sample flask.

Thorough shaking of the

sample flask for subsequent readings resulted in a more
even distribution of Candida in the SDB and the elimination of aberrant readings.
Dry weights of Candida grown in tissue culture
medium for 24 hours with and without SM-1213 present were
also very similar, as were the pH readings of the culture
supernatants (see Table 2).

The pH of the culture super-

natant was used as an indication of change in acidity of
the medium due to candidal growth.
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Table l. Effect of SM-1213 on the growth of Candida albicans
in Sabouraud's dextrose broth (SDB)a:
Incubation
time (hrs)

Growth of c.albicans at 37°C.b
'
SM-1213 concentration 1n
SDB ( JJ g7m1)
0
0.1
1.0
0.01
0.001

1

0.050

0.045

0.035

0.030

0.047

2

0.056

0.038

0.075

0.048

0.060

3

0.095

0.116

0.129

0.101

0.102

4

0.221

0.192

0.167

0.201

0.228

5

0.525

0.303

0.320

0.283

0.333

6

0.300

0.309

0.300

0.300

0.308

7

0.450

0.460

0.460

0.460

0.480

8

0.610

0.620

0.610

0.610

0.620

9

0.740

0.750

0.740

0.740

0.750

9.5

0.840

0.850

0.850

0.840

0.850

10

0.940

0.950

0.940

0.950

0. 950

a)lOO ml of SDB was inoculated with 1 X 105 c.a1bicans in
each of five 500 ml side-arm Erlenmeyer flasks containing
the specified concentration of SM-1213 at the time of inoculation.
b)Growth of C.albicans was monitored by the increase in turbidity of candidal cultures with time. Spectrophotometric
readings were taken at each time interval at 660 nm.
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Table 2. Effect of SM-1213 on the growth of Candida albicans
in tissue culture mediuma
SM-1213
concentration
in TC medium
( J.lg/ml)

pH of TCb
medium

Dry weightc
(grams)

0

7.35

0.0297

1.0

7.10

0.0291

0.1

7.24

0.0307

0.01

7.35

0.0311

0.001

7.35

0.0311

a)50 ml of HI-W05/BA2000 tissue culture medium was inoculated
with 1 X 105 C.albicans in each of five 250 ml Erlenmeyer
flasks and incubated for 24 hours on a rotary shaker at
37°C.
b)pH of supernatant TC medium in which c.albicans was grown.
c)Dry weight determinations of candidal-growth from (a) above
after 24 hours incubation at 37°C in TC medium. Cultures
were Millipore filtered, washed, and dried at 60°C for 48
hours.
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2.

Tissue Culture Studies

a.

Effect of SM-1213 on Germ Tube Elongation of Phagocytized Candida albicans in the Absence of Serum
In the first experiment employing paraffin oil

induced guinea pig peritoneal cells, two drug levels and
a control group were tested.

As demonstrated in Figure 2,

the average germ tube lengths were nearly identical in
the control group and the drug treated groups until the
6-hour sampling time.

At this point, the average germ

tube length in the control group was significantly higher
than in the SM-1213 treated samples.
The apparent lag in time before the divergence
between the control and drug groups would seem to indicate that there is a mechanism by which SM-1213 induces
a change in the ability of the peritoneal exudate cells
to inhibit the growth of intracellular Candida, but that
there is an interval before the peritoneal cells are
activated or before the activation can mediate an effect.
The lower drug concentration of SM-1213 (0.001
~g/ml)

inhibited germ tube elongation more efficiently

than did the higher drug concentration (0.01

~g/ml)

after

6 hours of incubation, while both drug treated groups
were significantly lower than the control.
Drug treated groups also showed the lowest intracellular viability (see Figure 3).

The differences in
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Figure 2. Effect of SM-1213 on germ tube elongation
of phagocytized Candida albicans in mineral oil induced exudate cells in the absence of serum.
Phagocytic leukocytes were induced by i.p. injection
of mineral oil into a male, Hartley strain guinea pig 72
hours prior to cell harvest. Germ tube lengths were measured
microscopically at lOOOX via a micrometer in the microscope
eyepiece. Each point represents the average germ tube length
(±S.E.) of 50 intracellular Candida cells measured at the
designated time interval. (e) Control; (•) 0.01 ~g SM-1213/ml
TC medium; (•) 0.001 ~g SM-1213/ml TC medium.
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Figure 3. Effect of SM-1213 on the viability of
phagocytized Candida albicans in mineral oil induced exudate
cells in the absence of serum.
Each data point represents the percentage of viable
Candida cells in 100 leukocytes containing fungus.
% Viability

=

# of Candida forming colonies
#of Candida
+#of Cand1da unable
forming colonies
to form colonies

X 100;

a colony was designated as four adjacent c.albicans yeast
cells formed on Sabouraud's dextrose agar-after two and onehalf hours of secondary incubation at 37°C. {e) Control;
{A) 0.01 ~g SM-1213/ml TC medium during initial incubation;
{•) 0.001 ~g SM-1213/ml TC medium during initial incubation.
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viability, unlike germ tube length, were apparent after
only 2 hours of incubation.

Thus, exposure to SM-1213

for as little as 2 hours can mediate an effect on candidal
viability.
Since percent viability is a measure of the ability
of candidal cells to emerge from within peritoneal cells
and form colonies on SDA, germ tube lengths do not strictly correlate with viability results during the first hours
of incubation when germ tubes are wholly contained within
leukocytes.

Apparently, during the subsequent

2~

hours

of incubation on SDA, germ tubes in the control sample
were better able to escape from within the peritoneal
cells and form colonies, even though their average length
at the 2- and 4-hour intervals in tissue culture were
comparable to drug treated groups.
It was noted also that, after 6 hours of incubation in tissue culture followed by incubation on SDA, the
control group formed massive colonies, which were greater
in size as well as in number than the drug treated
groups.

This indicates that the drug may be implicated

in the reduction of candidal division and multiplication
upon agar after exiting peritoneal cells as a result of
its effect on leukocytes while in tissue culture.

The

correlation between the average germ tube length and the
percent viable cells was strong by the 6-hour interval of
tissue culture, as will be discussed later.
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In an experiment where glycogen was used as an
inducing agent, germ tube elongation was more greatly
inhibited than in the paraffin oil induced experiment
above (see Figure 4).
~g/ml

The germ tube lengths in the 0.001

treatment group were significantly shorter than in

the control.

It was speculated that the hyphae were dis-

integrating rather than elongating due to the observed
loss of cell envelope integrity in treated samples.
All drug groups demonstrated shorter germ tube
lengths than the control.

Here, unlike the previous

experiment which used paraffin oil induction, the differences in germ tube lengths were apparent after 4 hours
of incubation time.
The effects of SM-1213 on the percent viable cells
in this study were also apparent.

All drug treated

groups showed lower viability than the control.
lowest concentration of drug (0.001

~g/ml)

The

showed the

lowest Candida viability and was significantly different
from the control (see Figure 5).
b.

Effect of SM-1213 on Germ Tube Elongation of Phagocytized Candida albicans in the Presence of Serum
Once again, paraffin oil was used as an inducing

agent in this study.

However, whole, normal guinea pig

serum was added to the tissue culture medium to determine
what effect it might have on germ tube elongation and
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Figure 4. Effect of SM-1213 on germ tube elongation
of phagocytized C.albicans in glycogen induced exudate cells
in the absence of serum.
Phagocytic leukocytes were induced by i.p. injection
of glycogen (0.1 % w/v in EBSS) into a male, Hartley strain
guinea pig 24 hours prior to cell harvest. Germ tube lengths
were measured microscopically at lOOOX via a micrometer in
the microscope eyepiece. Each point represents the average
germ tube length (±S.E.) of 50 intracellular Candida cells
at the designated time interval. (e) Control; <+) 0.1 ~g SM1213/ml TC medium; (A) 0.01 ~g SM-1213/ml TC medium; and
(T) 0.001 ~g SM-1213/ml TC medium.
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Figure 5. Effect of SM-1213 on the viability of
phagocytized Candida albicans in glycogen induced exudate
cells in the absence of serum.
Each point represents the percentage of viable
Candida cells in 100 leukocytes containing fungus. Percentage viability was determined as in Figure 3. (e) Control;
(+) 0.1 ~g SM-1213/ml TC medium during initial incubation;
(A) 0.01 ~g SM-1213/ml TC medium during initial incubation;
(•) 0.001 ~g SM-1213/ml TC medium during initial incubation.
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candidal viability.

In this study (see Figure 6), signif-

icant differences in average germ tube length were not
observed.
When compared to Figure 2, where paraffin oil was
used but no serum was added, the overall average germ
tube length of the control sample at the 6-hour interval
was significantly less in the presence of serum.

It would

appear from this data that the addition of serum to the
tissue culture fluid inhibits the rapid elongation observed in the first serum-free experiment between the
4- and 6-hour interval.

Serum did not significantly

reduce the average germ tube length of drug treated
samples, although some reduction was apparent (see upper
half of Table 3).

It is speculated that SM-1213 may

mimic an unknown serum factor which may stimulate peritoneal cells to inhibit germ tube elongation.
Although no significant differences were noted in
average germ tube length, the lowest dose of SM-1213
(0.001

~g/ml)

was significantly effective in reducing

Candida viability at the 6-hour interval (see Table 4).
In addition to germ tube length and viability,
the percentage of peritoneal exudate cells containing
intracellular Candida was determined for each interval.
This was calculated by counting 100 peritoneal cells in
each test group.

The percentage of these cells which

contained Candida was then determined.
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Figure 6. Effect of SM-1213 on germ tube elongation
of phagocytized Candida albicans in mineral oil induced exudate cells in the presence of serum.
Procedures were identical to those described in Figure 2 except, in this case, 2% v/v whole, normal guinea pig
serum was added to the incubation medium. Each point represents the average germ tube length (±S.E.) of 50 intracellular Candida cells at the designated time interval. (e) Control:(~) 0.1 ~g SM-1213/ml TC medium; (A) 0.01 ~g SM-1213/ml
TC medium; (T) 0.001 ~g SM-1213/ml TC medium.
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Table 3. Effect of SM-1213 on the germ tube length of Candida
albicans in the presence or absence of serum
SM-1213
concentration
( llg/ml) b

Average germ tube length (ll)

a

Without serum

With serumc

Significance
leveld

0

52.68 ± 3.83g

27.94 ± 3.30

p < 0.001

0.001

27.68 ± 3.30*

20.82 ± 3.00

N.S.

0.01

39.28 ± 3.80*

32.82 ± 3.86

N.S.

0

9.34 ± 1.74

6.80 ± 1.58

N.S.

0.001

3.94 ± 0.72*

3.80 ± 0.91

N.S.

0.01

6.28 ± 1.31

3.12 ± 1.03*

N.S.

Hineral oile

Glycogenf

a)50 C.albicans cells contained within leukocytes were measured for germ tube length after 6 hours of incubation time
in HI-W0 5 /BA 2000 tissue culture medium at 37°C, 5% C0 2 •
Germ tube lengths were measured by the use of a micrometer
in the eyepiece of a microscope at lOOOX.
b)Incubation medium contained the specified concentration of
SM-1213.
c)Incubation medium contained 2% v/v whole, normal guinea
pig serum.
d)N.S. indicates P > 0.05 by Student's t test.
e)Mineral oil was used as an inducing agent for leukocyte
harvest; 20 ml was injected i.p. into a male, Hartley
strain guinea pig 72 hours prior to cell harvest.
f)Glycogen was used as an inducing agent; 20 ml of a 0.1%
w/v solution of glycogen in Earle's balanced salt solution
was injected as in (e) above except 24 hours prior to cell
harvest.
g)Average germ tube length in microns plus or minus the
standard error of the mean (±S.E.); an asterisk (*) following the S .E. indicates a significant (P < 0. 05) difference in germ tube length between the drug treated and
control sample by Student's t test.
Data was compiled from four experiments.
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Table 4. Effect of SM-1213 on the viability of phagocytized
Candida albicans in mineral oil induced exudate
cells 1n the presence of seruma
SM-1213
concentration
(llg/ml) b

Percentage viable C.albicansC
Incubation time (hours) d
2

0

N.D.e

4

6

74

79

0.001

62

64

56*f

0.01

70

72

74

0.1

65

60

72

a)Initial tissue culture incubation medium contained 2% v/v
whole, normal guinea pig serum.
b)Leukocyte + Candida mixtures were exposed to the specific
SM-1213 concentrations noted above contained in HI-WOs/
BA 2000 tissue culture medium during the initial incubation
time at 37°C, 5% C0 2 •
c)Percentage viable cells was determined as in Figure 3.
d)Initial incubation time in TC medium before the additional
two and one-half hours of incubation on Sabouraud's dextrose agar at 37°C.
e)N.D. = not done.
f)An asterisk (*) denotes a significantly reduced percentage
viability of C.albicans between the control and drug
treated samples (P<O.OOl by x 2 analysis).
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Theoretically, if all extracellular Candida were
removed by the wash with medium at the 2-hour interval,
the percentage of leukocytes containing Candida intracellularly should remain constant at each sampling time
for any given group.

The percentages ranged from as low

as 13% at 2 hours after incubation to as high as 20%
after 6 hours of incubation.

The initial ratio of Candida

to peritoneal cell was 1:10 to 1:5 (10-20%) in all experiments.

No significant differences were observed over

time in the percentage of exudate cells containing intracellular Candida.

In addition, virtually all Candida

used as an inoculum was apparently phagocytized.
A cell-free sample of tissue culture medium was
also inoculated with Candida.

This was done to insure

that intracellular Candida which remained in the yeast
form (hyphal length = 0

~)

did so due to the influences

of the peritoneal cells present (see upper half of Table
5).

At the 2-hour interval, 88% of all Candida cells

had developed into the hyphal form; by 6 hours, 94% produced hyphae.

Clearly, the majority of Candida cells,

when not influenced by peritoneal cells, develop into
the hyphal form in the tissue culture medium tested (HIW05/BA2000 with 2% whole, normal guinea pig serum).
longest hypha observed in this study ranged from 62
the 2-hour time interval to 115

~

The
~

at

at the 6-hour interval.

The longest hypha at the 4-hour interval measured 75

~·
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Table 5. Effect of tissue culture medium on candidal morphology in the presence of seruma
Percentage of Candida in hyphal forme
Experiment
numberb

Incubation time (hours)
2

4

6

1

88

92

94

2

90

95

N.D.

d

a)3 ml of HI-W0 5 /BA 2000 tissue culture medium containing 2%
v/v whole, normal guinea pig serum was inoculated with
4 X 10 5 yeast cells in the absence of leukocytes and incubated at 37°C, 5% C0 2 •
b)Experiment #1 was conducted in parallel with an experiment
utilizing mineral oil induction and experiment #2 was conducted in parallel with an experiment utilizing glycogen
induction.
c)50 Candida were counted from tissue culture samples at the
intervals indicated above and examined for the formation
of germ tubes. The number of c.albicans displaying germ
tube formation divided by the-total number of yeast and
hyphal forms present X 100 = % of Candida in hyphal form.
d)N.D. = not done.
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Lastly, studies were performed in which glycogen
induced peritoneal exudate cells were incubated with
whole, normal guinea pig serum added to the tissue culture medium (see Figure 7).

In this study, which was

performed blind, the drug groups once again showed significantly less germ tube elongation than the control.
However, unlike the other experiments discussed, the
highest drug concentration appeared to be the most efficient in inhibiting intracellular Candida growth.
All drug groups demonstrated significantly fewer
viable Candida cells than the controls under the influence of serum (see Figure 8 and Table 6).
The percentage of Candida in hyphal form in samples
containing no exudate cells was determined as in the
previous experiment to confirm that inhibition of germ
tube elongation was truly due to the presence of leukocytes (see lower half of Table 5) .

Both the glycogen

induced and paraffin oil induced studies contained serum
in the tissue culture medium and, in both, approximately
90% of the Candida cells developed into the hyphal form
by 2 hours of incubation.
The range in hyphal length was marginally greater
in this study than in the last when comparing lengths of
the longest germ tube observed at a particular time
interval.

After 2 hours of incubation, the longest hypha
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Figure 7. Effect of SM-1213 on germ tube elongation
of phagocytized Candida albicans in glycogen induced exudate
cells in the presence of serum.
Procedures were identical to those described in Figure 4 except, in this case, 2% v/v whole, normal guinea pig
serum was added to the incubation medium. Each point represents the average germ tube length (±S.E.) of 50 intracellular Candida cells at the designated time interval. (e) Control;(+) 0.1 ~g SM-1213/ml TC medium;(£) 0.01 ~g SM-1213/ml
TC medium; (T) 0.001 ~g SM-1213/ml TC medium.
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Figure 8. Effect of SM-1213 on the viability of
phagocytized Candida albicans in glycogen induced exudate
cells in the presence of serum.
Each point represents the percentage of viable
Candida cells in 100 leukocytes containing fungus. Percentage v1ability was determined as in Figure 3. (e) Control;
(+) 0.1 ~g SM-1213/ml TC medium during initial incubation;
(A) 0.01 ~g SM-1213/ml TC medium during initial incubation;
(T) 0.001 ~g SM-1213/ml TC medium during initial incubation.
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Table 6. Effect of SM-1213 concentration on the viability of
intracellular Candida albicans in the presence or
absence of serum

SM-1213
concentration
(~g/ml)b

Percentage viable Candida albicans

a

Glycogen d

Mineral oilc
No serum

Serum e

No serum

Serum

85

79

54

52

0.001

66*f

56*

34*

34*

0.01

75

74

42

30*

72

47

35*

0

0.1
a)% Viability=

N.D.g

e

#of Candida forming colonies
X lOO;
# of Candida
# of Candida unable
forming colonies + to form colonies

a colony was designated as four adjacent C.albicans yeast
cells formed on Sabouraud's dextrose agar-after two and
one-half hours of incubation at 37°C. 100 leukocytes were
counted for each percentage.
b)Leukocyte +Candida mixtures were exposed to the specific
SM-1213 concentrations noted above contained in HI-W0 5 /
BA 2000 tissue culture medium during the initial 6 hours
of incubation at 37°C, 5% C0 2 •
c)Mineral oil was injected i.p. into a guinea pig 72 hours
prior to leukocyte harvest.
d)Glycogen (0.1% w/v in EBSS) was injected i.p. into a
guinea pig 24 hours prior to leukocyte harvest.
e)Initial incubation medium contained 2% v/v whole, normal
guinea pig serum.
f)An asterisk (*) indicates a significant difference in percentage viable c.albicans between control and drug treated samples (P < 0.05 by the x2 analysis). In addition, glycogen induced cells demonstrated a significantly reduced
candidal viability relative to mineral oil induced cells
in the presence or absence of serum (P < 0.01 by x2 analysis).
g)N.D. =not done.
Data was compiled from four experiments.
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observed measured 37

~'

at 4 hours 94

~'

and at 6 hours

no reading was taken.
The average germ tube length in the cell-free
sample was significantly greater than any test group
containing peritoneal cells and is illustrated in Table 7.
The addition of serum to the tissue culture medium
had the effect of reducing the average germ tube length
for every group tested which contained cells (see lower
half of Table 3).

Serum had a similar inhibitory effect

on the average germ tube length in the paraffin oil induced experiments, but only in the control group at the
6-hour sampling time was a significant difference noted.
Although the average germ tube length was not
significantly affected by serum in comparable glycogen
samples, the frequency of Candida remaining in the yeast
form after 6 hours incubation was significantly affected
(see Table 8).

Therefore, there apparently was an effect

mediated by the addition of serum which inhibited hyphal
formation in glycogen induced cells (control and drug
treated) as well as in the control paraffin oil induced
cells.

Drug treated cells from the paraffin oil induced

studies were once again not significantly affected by the
addition of serum.
Average germ tube length closely correlated to the
percent viability as determined in these studies.

The
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Table 7. Effect of glycogen induced exudate cells on germ
tube elongation of phagocytized Candida albicans
in the presence of seruma
Average germ tube length
Experimental
group

(~)

b

Incubation time (hours)
2

4

6

2.86 ± 0.89*

6.80 ± 1.58

Leukocytes

+ mediumc
.

d

Me d lUm

1.04 ± 0.28*e
16.10 ± 1.55

34.66 ± 3.85

N.D.f

a)2% v/v whole, normal guinea pig serum was added to the incubation medium.
b)SO candidal cells were measured for germ tube elongation
by the use of a micrometer in the eyepiece of a microscope
at lOOOX at the intervals detailed above. Average germ
tube lengths are represented plus or minus the standard
error of the mean (±S.E.).
c)3 ml of HI-W0 5 /BA 2000 tissue culture medium containing
serum as detailed in (a) was inoculated with 4 X 10 5 yeast
cells in the presence of 2 X 106 glycogen induced peritoneal cells and incubated at 37°C, 5% C0 2 .
d)3 ml of HI-W0 5 /BA 2000 tissue culture medium containing
serum as detailed in (a) was inoculated with 4 X 10 5 yeast
cells in the absence of exudate cells and incubated at
37°C, 5% C0 2 for the indicated time intervals.
e)An asterisk (*) indicates a significantly reduced average
germ tube length of Candida in samples containing exudate
cells (P < 0. 01 by Student's t test) .
f)N.D. = not done.
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Table 8. Effect of SM-1213 concentration on the morphology
of phagocytized Candida albicans in the presence
or absence of serum
SM-1213
concentration
( )lg/ml) a

Frequency of Candida albicans
in yeast formb
No serum

Serumc

Significance
levelf

Mineral oild
0

0/50

11/50

0.001

4/50

9/50

N.S.

0.01

1/50

5/50

N.S.

Glycogen

P<O.OOl

e

0

29/50*

p < 0. 001

0.001

17/50

30/50

p < 0. 01

0.01

17/50

39/50

p < 0. 001

0.1

11/50

42/50

p < 0. 001

a)Leukocyte + Candida mixtures were exposed to the specific
SM-1213 concentrations noted above contained in HI-W0 5 /
BA 2000 tissue culture medium during the initial 6 hours of
incubation at 37°C, 5% C0 2 •
b)50 C.albicans cells contained within leukocytes were examined for germ tube formation after 6 hours of incubation
time under the conditions described in (a).
c)Incubation medium contained 2% whole, normal guinea pig
serum.
d)Mineral oil was used as an inducing agent for leukocyte
harvest; 20 ml was injected i.p. into a male, Hartley
strain guinea pig 72 hours prior to cell harvest.
e)Glycogen was used as an inducing agent; 20 ml of a 0.1%
w/v solution of glycogen in EBSS was injected as in (d)
above except 24 hours prior to cell harvest.
f)N.S. indicates P < 0.05 by the x2 analysis.
g)Glycogen induced leukocytes demonstrated a significantly
greater number of Candida cells in the yeast form than the
mineral oil induced cells in the presence of serum
(P< 0.05 by the x2 analysis).
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correlation was strongest in the absence of serum in both
the glycogen and paraffin oil studies (Pearson's r =
0.99).

The correlationwasmoderately strong in the par-

affin oil study with serum (r = 0.74) and strong in the
glycogen study with serum added (r

=

0.94).

As will be discussed later, the differences in the
cell type which predominated in the peritoneum as a result
of the inducing agent employed may provide an explanation
for the differences observed between paraffin oil induced
cells and glycogen induced cells.

The predominant cell

type produced upon 72-hour paraffin oil induction was the
macrophage, whereas the predominant cell type upon 24-hour
glycogen induction was the polymorphonuclear leukocyte.
As demonstrated in Table 9, not only was the effect
of serum on the germ tube length different upon paraffin
oil induced cells than glycogen induced cells, but the
overall length attained by germ tubes after 6 hours incubation was significantly lower in glycogen induced cells.
In addition, glycogen induced cells also demonstrated a
lower percentage of hyphal forms of Candida in the presence and absence of serum than did the paraffin oil
induced cells.

These attributes may reflect the greater

candidacidal activity of the polymorphonuclear neutrophil.
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Table 9. Effect of serum on germ tube formation in phagocytized Candida albicans in tissue culture
Leukocyte
inducing
agentb
Mineral
oil
Glycogen

Average germ tube length ( ll) a
c
Serum
No serum
52.68 ± 3.83
(100%)e
9.34 ± 1. 74*£
(84%)*

27.94 ± 3.69
(7 8%)
6.80 ± 1. 58*
(42%) *

Significance
leveld

p < 0. 001
N.S.

a)SO C.albicans cells contained within leukocytes were measured for germ tube length after 6 hours of incubation time
in HI-W0 5 /BA 2000 tissue culture medium at 37°C, 5% C0 2 •
Germ tube lengths were measured by the use of a micrometer
in the eyepiece of a microscope at lOOOX.
b)20 ml of mineral oil or glycogen (0.1% w/v in EBSS) was
injected i.p. into a male guinea pig 72 or 24 hours prior
to leukocyte harvest respectively.
c)Incubation medium contained 2% v/v whole, normal guinea
pig serum.
d) N. S. = not significant (P > 0. 05 by Student's t test) .
e)Percentages in parentheses indicate the percentage of 50
intracellular Candida cells which developed germ tubes
(hyphae) after 6 hours of incubation time as described in
(a). Although the addition of serum did not significantly
reduce the germ tube length of Candida in the glycogen
induced studies, the percentage of Candida in hyphal form
was significantly reduced (P < 0. 001 by x 2 analysis) by the
addition of serum to the culture medium. In addition, the
presence of serum in the culture medium significantly reduced the percentage of hyphae formed in the mineral oil
induced studies as well (P < 0. 001 by x2 analysis) .
£)Glycogen induced leukocytes demonstrated a significantly
reduced germ tube length relative to mineral oil induced
cells in the presence or absence of serum (P < 0. 001 by
Student's t test) as well as a significantly reduced percentage of Candida in hyphal form (P < 0.01 by x 2 analysis)
as indicated by asterisks above.
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B.

In Vivo Studies

1.

Intravenous Inoculations

a.

Computation of the 50% Lethal Dose (LDso) of Candida
albicans
The results for the determination of the 50% lethal

dose for the strain of Candida albicans used in the following experiments is shown in Table 10.
intravenous dose of 1 X 10 5

•

88

By day 11, an

Candida cells, grown for

24 hours on SDA at 37°C, will be lethal to 50% of male,
Ha/ICR mice used experimentally.

Initial intravenous

experiments were primarily concerned with early mortality
occurring within the first week following infection where
high doses of Candida were used as inocula.

Day 11 was

therefore chosen for the termination of tbe LDso study.
Subsequent experiments in which low inocula were used
were conducted for more prolonged periods and mortality
was observed for approximately 30 days, although no further LD 50 studies were conducted.
b.

Effect of SM-1213 on Mortality of Mice Infected Intravenously with Candida albicans
A series of studies were undertaken to determine

the effect of SM-1213 drug administration on intravenously infected Ha/ICR mice.

SM-1213 therapy for 24 hours

only beginning either on the day of infection (day 1) or
24, 48, or 72 hours post-infection was examined.

SM-1213

Table 10. Computa·tion of the 50% lethal dose (LD 50 )* for Candida albicans by day eleven
post-infection.
Accumulated values
Mortality
ratio

Died

Survived

Total
dead

Total
survived

Ratio

% Dead

1 X 10 8

8/8

8

0

19

0

19/19

100

1.5 X 10 7

7/8

7

1

11

1

11/12

92

1 X 10 6

4/6

4

2

4

3

4/7

57

1 X 10 5

0/6

0

6

0

9

0/9

0

Candida dose
injected i.v.

Mortality

*Calculation of the LD 50 from the above data:
% Mortality at dilution next above 50% - 50%
%Mortality at dilution next above 50%-% Mortality-at dilution next below 50%

=

Proportionate distance between known % mortality
and 50% mortality
Therefore, 57% - 50%
= 0.12
57% - 0%

Or, the LD 50 titer= 105.88

(j)
,j:::.
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was administered in the drinking water at a dosage of 80
~g/kg/day

based on average consumption per average as-

sessed animal weight.
In male, Ha/ICR mice infected with 2 X 10 5 Candida
cells intravenously and treated 48 hours later with SM1213 for 24 hours, a significant reduction in mortality
was observed when compared to control mice (see Figure 9).
In order to substantiate these results, two additional experiments were conducted under the same experimental protocol as the first.

Table 11 illustrates the

cumulative mortality for all three experiments conducted
utilizing the day 3-4 drug treatment regimen.

Significant

differences were obtained between the drug treated and
control groups in
day 24.

cumulat~ve

mortality from day 18 to

Table 12 illustrates the continued significant

differences on day 27 and day 30 in two of the three
experiments.

The third experiment was altered on day 24

and the results beyond this day (and therefore before
this day) could not be included in this table.

Mortality

plateaued in all test groups from day 27 until experimental termination.
In addition, alternate intervals of drug administration were tested (see Table 13).

Various intervals of

24-hour drug treatment were tested in these experiments:
1)

drug treatment begun on the day of infection for 24
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Figure 9. Effect of SM-1213 therapy on the cumulative
mortality of mice infected intravenously with Candida albicans.
Male, Ha/ICR mice were injected intravenously with
2 X 10 5 c.albicans cells on day 1. Drug treated mice received 80 ~g-SM-1213/kg/day orally in drinking water for day 3
to day 4 only; control mice received no drug. (e) Control,
N = 15; (+) SM-1213 treated, N = 15.
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Table 11. Effect of SM-1213 treatment on the cumulative percentage mortality in mice
infected intravenously with Candida albicansa
Cumulative % mortalityb

Treatment
group

(Number of

Day 9

Day 12

Day 15

Day 18

Day 21

Day 24

experiments)

Control

3

25

41

53

58

64

(3)
N=59

SM-1213c

3

18

28

34*d

38*

43*

( 3)

N=61

a)Male, Ha/ICR mice were infected intravenously with 2 X 10s C.albicans cfu on day 1
and observed for the occurrence of death.
b)The cumulative percentage mortality was determined for the days indicated above by
determining the total number of mice dead by that day divided by the total number
of experimental animals X 100. N = the total number of mice used experimentally.
c)Drug treated mice received 80 ~g SM-1213/kg/day orally in the drinking water for
24 hours only from day 3 to day 4 post-infection.
d)An asterisk (*) indicates a significant reduction in cumulative mortality in drug
treated mice relative to control mice (P < 0.05 by x 2 analysis).

0\
Cf)

Table 12. Effect of SM-1213 treatment on the thirty day cumulative mortality in mice
infected intravenously with Candida albicansa
Treatment

Cumulative % mortalityb

(Number of

Day 9

Day 12

Day 15

Day 18

Day 21

Day 24

Day 27

Day 30

experiments)

Control

5

38

57

62

68

78

78

78

(2)
N=37

SM-1213c

8

21

32*d

42

42*

45*

50*

50*

group

( 2)

N=38

a)Male, Ha/ICR mice were infected intravenously with 2 X 10 5 c.albicans cfu on day 1
and observed for the occurrence of death for thirty days.
b)The cumulative percentage mortality was determined as indicated in Table 11. N =
the total number of animals used experimentally.
c)Drug treated mice received 80 ~g SM-1213/kg/day orally in drinking water for 24
hours only for day 3 to day 4 post-infection.
d)An asterisk indicates P < 0.05 by the x2 analysis between control and drug treated
group mortality.

ffi
~

Table 13. Effect of SM-1213 treatment on the cumulative mortality of mice infected intravenously with Candida albicans and treated with SM-1213 at various intervalsa
Average cumulative % mortalityb

Treatment

(Number of
experiments)

Day 9

Day 12

Day 15

Day 18

Day 21

Day 24

4(±2)c

28(±12)

43(±16)

54 (±9)

59(±9)

67(±14)

(3) N=59

**Day 1-2

7 ( ± 7)

22 (±9)

33(±16)

48(±18)

61 (±13)

68(±11)

(2) N=46

**Day 2-3

2 ( ±2)

9(±5)*d

20(±7)*

34(±7)*

48 (±7)

61(±11)

(2) N=44

**Day 3-4

6 ( ±4)

17(±4)

26 (±9)

34(±8)*

37(±6)*

42(±3)*

(3) N=61

**Day 4-5

5(NA)e

14(NA)

23(NA)

27(NA)*

27(NA)*

32(NA)*

(1) N=22

group
Control

a)Male, Ha/ICR mice were infected intravenously with 2 X 10 5 Candida albicans cells on
day 1 and observed for the occurrence of death. Drug treated mice received 80 ~g SM1213/kg/day orally in drinking water for 24 hours only for the interval designated by a
double asterisk above (**).
b)The cumulative mortality for each designated time interval from day 9 to day 24 was determined by averaging the cumulative mortality of animals from multiple experiments.
c)The average cumulative percentage mortality is expressed plus or minus the standard
error of the mean (±S.E.).
d)An asterisk (*) following the S.E. indicates a significant reduction in average cumulative mortality in drug treated mice relative to control mice (P < 0.05 by x2 analysis).
e)NA = not applicable.
-J
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hours only (designated as day l-2 therapy), 2) treatment
begun on the day following infection (day 2-3), 3) treatment begun 2 days following infection (day 3-4), and 4)
treatment begun 3 days following infection (day 4-5).
Table 13 represents the average cumulative percentage
mortality for all three experiments.

The earliest sig-

nificant difference in mortality between drug and control
groups occurred in the day 2-3 treated group.

However,

mortality continued to rise in the day 2-3 treated mice
and was not significant from the control group on day
21 or 24.

The day 3-4 treated group showed a significant-

ly lower cumulative mortality than controls during experimental continuation from day 18 to day 24.

Day 4-5 data

was included in this table even though-one experiment was
conducted using this regimen and was not conclusive evidence that a significant difference between control and
drug groups was truly present.

The day 4-5 treated group

showed a significantly lower cumulative mortality than
the average control from day 18 to day 24.

However, this

treatment group was not significantly different from its
own experimental control.

There was an indication that

further experiments, which would increase experimental
numbers, would have shown a significant difference, since
multiplication of the data from this one experiment by
three produces a significant difference between control
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and day 4-5 treated groups from day 20 to day 24.

There

is strong evidence to support the effectiveness of day
3-4 drug therapy, however, in the reduction of overall
cumulative mortality and a suggestion that day 4-5 therapy
may be effective as well.
In addition, day 3-4 and day 4-5 drug therapy were
significantly more effective in reducing cumulative mortality than day 1-2 drug therapy on day 21 and 24.

Day

4-5 drug therapy was also more effective than day 2-3
drug therapy on day 24.

Such data supports the suggestion

that specific intervals of drug therapy are important in
the effectiveness of SM-1213 in reducing mortality.
In order to quantitate the number of yeast cells
in the viscera of mice inoculated with Candida albicans,
tissue homogenate studies were conducted.

Since the

kidney is an organ of major involvement in candidal infections

(26,66), it was of interest to culture these

organs from infected animals.

On day 32, surviving mice

were killed by cervical dislocation and kidneys were
aseptically removed and homogenized.
Significant differences were not observed between
any of the test groups at this sacrifice time.

The aver-

age number of Candida cells per two kidneys homogenized
varied from as low as 1 X 10~
animals to 1.7 X 10 5

(±0.64) for the drug treated

(±1.7) for the control animals.
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2.

Effect of SM-1213 on the Course of Leg Lesions in Mice
Infected Intramuscularly with Candida albicans
A series of experiments were conducted utilizing

the mouse leg lesion model for experimental candidiasis.
Animal weights, as well as abscess sizes, were monitored
at intervals throughout infection.

In addition, absces-

ses, kidneys, and/or spleens were either 1) homogenized
in order to quantitate Candida present or 2) cultured in
order to determine the presence of Candida within these
tissues.
The CBA/J strain of mouse was determined to be
suitable for these studies, since it consistently produced measurable abscesses with the inocula used in these
experiments.

The CBA/J inbred strain of mouse provided

a more genetically homogeneous population than did the
randomly-bred Ha/ICR strain of mouse; this would have
been particularly important had lymphoid cell transfer
studies been undertaken.

In addition, the temperament

of the CBA/J mouse was more docile than that of the Ha/ICR
mouse, which not only allowed for easier handling of the
mice but also eliminated interference with experimental
data due to fighting among cohabitating males as observed
in the Ha/ICR strain.
The inbred C3H strain proved to be less susceptible
than the CBA/J strain to Candida lesion formation and

7~

required twice the inoculum of Candida to produce an
abscess equivalent in size to that of the CBA/J strain.
Another inbred strain of mouse, the Balb/c strain, was
also found to be unsuitable for leg lesion studies, since
spontaneous amputation of the infected limbs occurred by
day 7 in 10% of the mice inoculated.

Such amputation

was attributed to a hyperimmune response, since mice
immunosuppressed with 300 mg of cyclophosphamide/kg four
days prior to infection did not amputate their limbs or
develop localized abscesses.

Such a dose of cyclophospha-

mide has been shown to reduce white blood cell counts in
mice 100-fold by day 4 (58).

However, immunosuppressed

mice subsequently died of apparent systemic infection;
by day 12, mortality reached 78%.

Therefore, the CBA/J

strain of mouse was utilized in the following studies.
a.

Leg Lesion Study #1:

Effect of SM-1213 on the Course

of Leg Lesions in Mice Infected Intramuscularly with
1.25 X 10 8 Candida albicans Cells
In this study, designated as Leg Lesion Study #1,
male CBA/J mice were infected with 1.25 X 10 8 Candida
cells per mouse intramuscularly into the right calf.
Leg swelling was measured on day 1, 2, 3, 6, 7, 8, 10,
13, 15, 17, 20, 22, and 24.

Drug therapy (80

~g/kg/day)

was administered from day 3 to 4 for one treatment group
and day 4 to 5 for the other treatment group.

As shown
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in Figure 10, there were no significant differences in
abscess sizes between drug and control groups until day
24.
Animal weights, however, were significantly higher
in drug treated animals

(see Figure 11) , which suggested

that these animals were in better overall health (57);
SM-1213 has no caloric value due to the substitutions
present on the monosaccharide molecule.

The average

group weight change from prior to infection to various
intervals post-infection is shown in Figure 11.

Drug

treated mice more closely paralleled the weight gain
pattern demonstrated by uninfected control mice than did
the infected controls.
When differences in animal weights were corrected
for any contributions the abscess sizes may have added,
the significant differences in animal weight between the
drug treated and control mice were actually enhanced
moderately (P<0.02 on day 8, P<O.Ol on day 15, and P
was the same on day 22).
In addition, when convalescing mice were analyzed
for Candida content in spleens on day 24, it was discovered that the day 4-5 drug treated groups had a significantly lower incidence as well as number of Candida
than controls (see Table 14).

'-l
(j)

Figure 10. Effect of SM-1213 on the course of leg lesions in mice infected
intramuscularly with 1.25 X 108 Candida albicans cells.
Candida cells were injected on day 1. Leg swelling was measured at the designated time 1ntervals with the aid of a Schnellt~ster numerical dial caliper. Drug
treated groups received 80 ~g SM-1213/kg/day orally in drinking water either for
day 3 to day 4 post-infection (Rxl) or for day 4 to day 5 post-infection (Rx2) . The
original number of mice in each test group was as follows: (e) Control, N = 14;
(•) day 3 to 4 drug treated group, N = 14; and (~) day 4 to 5 drug treated group,
N = 14.
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Figure 11. Effect of SM-1213 on the average group
weight change fro~ day one in mice infected intramuscularly
with 1.25 X 108 Candida albicans cells.
CBA/J mice were weighed prior to infection on day 1
and on days thereafter as indicated at right. The difference
between the average group weight on day 1 and on subsequent
days was plotted. The original number of test animals was
as follows: (•) Control, N = 14; (T) day 4 to 5 drug treatment group (as described in Figure 10), N = 14; (A) day 3
to 4 drug treatment group (as described in Figure 10),
N = 14; and uninfected control group (injected with PBS only
in the right leg), N = 8, represented at right by a star.
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Table 14. Effect of SM-1213 on the number of Candida albicans
recovered from spleens of convalescing micea

Interval b

Frequency of spleens
containing
viable C.albicansc

Control

13/14

13/14

Day 4-5

8/14

4/14

Treatment

Frequency of spleens
containing ~ 50 d
viable C.albicans

a)Male, CBA/J mice were injected intramuscularly in the right
calf with 1.25 X 10 8 c.albicans cells on day 1. On day 24,
mice were sacrificed;-spleens were excised, homogenized and
assessed for colony forming units on SDA at 37°C.
b)Control mice received no drug; drug treated mice received
80 ~g SM-1213/kg/day orally in the drinking water for 24
hours only from day 4 to day 5 post-infection.
c)Control mice versus drug treated, P < 0.05 by x2 analysis.
d)Control mice versus drug treated, P < 0.001 by x2 analysis.
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These results suggest that the drug treated groups
were better able to contain the abscess and prevent the
systemic spread of the infection.

However, no significant

differences were obtained between drug and control mice
in tissue homogenates of the kidneys (1.15 X 10 3 ± 0.29
versus 2.81 X 10 3 ± 0.68) when such high levels of Candida
were injected.

An alternative suggestion would be that

drug treated mice were better able to clear Candida from
the spleens by day 24.
b.

Leg Lesion Studies #2 and #3:

Effect of Altered

SM-1213 Drug Regimen and Method of Drug Administration
on Mice Infected Intramuscularly with Candida albicans
An inoculum similar to that used in Leg Lesion
Study #1 was used (1.2 X 10 8 Candida cells per mouse) and
CBA/J mice were inoculated intramuscularly into the right
leg.

However, in these studies drug regimen was altered.

Also, the method of drug administration was altered in
one of the following two experiments.
In addition to administering drug by drinking water
only, the method of gavaging animals to administer drug
was initiated.

In Leg Lesion Study #2, day 4-5 drinking

water treatment was given as in Leg Lesion Study #1 (80
~g/kg/day);

however, an additional drinking water dose

was also given for day 7-11 (400

~g/kg/day).

In Leg

Lesion Study #3, gavage doses were given for day 1-4 (400
~g/kg/day)

, followed by drinking water administration
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of drug for day 7-11 (400
~g/kg/day).

~g/kg/day)

and day 17-18 (80

See Figures 12 and 13.

Using these drug regimens, significant differences occurred between abscess sizes of drug treated
and control groups.

Drinking water therapy showed the

most significant differences early in the infection,
while gavage therapy demonstrated greatest significance
later in infection.
Tissue homogenization of kidneys and spleens was
carried out on day 46 post-infection.

No significant

differences were found in the spleens as in Leg Lesion
Study #1, where mice were sacrificed on day 24.

How-

ever, almost twice the number of Candida was found in
control kidneys as compared to mice treated with drug
by gavage.
c.

Sustained Effect of SM-1213 Treatment on Mice from
Leg Lesion Study #2 Reinoculated Intramuscularly
with Candida albicans
The recovered mice from Leg Lesion Study #2 were

reinfected on day 57 in the uninfected leg with 1 X 10 5
Candida cells per mouse intramuscularly (i.e. left leg
was injected) .

Significant differences were detected

between control and previously drug treated groups on
day 4 and 5 following reinoculation (see Figure 14).
The significant differences observed in the reinfected

ro
w

Figure 12. Effgct of altered SM-1213 drug regimen on mice infected intramuscularly with 1.2 X 10 Candida albicans cells.
Leg swelling was measured at the days indicated above with the aid of a
Schnellt~ster numerical dial caliper. Drug treated groups received 80 ~g SM-1213/kg/
day for day 4 to day 5 post~infection as in the initial leg lesion study as well as
an additional 400 ~g SM-1213/kg/day drug treatment for day 7 to day 11. All drug was
administered in the drinking water. (e) Control, N = 12; (0) SM-1213 treated, N = 12.
Points of significant differences in leg swelling between control and drug treated
groups is indicated below by a star.
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Figure 13. Effect of altered method of SM-1213 administration on mice infected intramuscularly with 1.2 X 10 8 Candida albicans cells.
Leg swelling was measured at the days indicated above with the aid of a
Schnellt~ster numerical dial caliper. Drug treated groups received 400 ~g SM-1213/kg/
day by gavage for day 1 to day 4, 400 ~g SM-1213/kg/day in drinking water for day 7
to day 11, and 80 ~g SM-1213/kg/day in drinking water for day 17 to day 18. (e) Control, N = 12; (0) SM-1213 treated, N = 14. Points of significant differences in leg
swelling between control and drug treated groups is indicated below by a star.
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Figure 14. Sustained effect of SM-1213 treatment on
mice reinoculated intramuscularly with Candida albicans.
CBA/J mice, originally infected l.m. Wlth 1.2 X 108
Candida albicans cells were reinoculated in the contralateral leg Wlth 1 X 105 Candida cells on day 57 post-initial infection. No additional drug therapy was given. (e) Control,
N = 11; (•) SM-1213 treated, N = 10.
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mice occurred without additional drug administration.
Thus, SM-1213 therapy exerted an effect long after the
initial infection had been resolved.
d.

Leg Lesion Study #4:

Effect of SM-1213 on the Course

of Leg Lesions in Mice Infected Intramuscularly with
7 X 10 6 Candida albicans Cells
In an attempt to reduce systemic infection and to
produce a localized, limited lesion, the dosage of Candida
injected intramuscularly was reduced in the following two
experiments.

Male, CBA/J mice inoculated with 7 X 10 6

Candida cells per mouse were monitored regularly for leg
swelling, as shown in Figure 15.

Drug was administered

in the drinking water for day 4 to 5 (80
day 7 to ll (400

~g/kg/day).

~g/kg/day)

and

Significant differences

between control and drug treated abscess sizes were obtained with this Candida dosage and drug regimen.
Tissue homogenates of spleens and kidneys of both
control and drug treated mice were negative for any candidal colony forming units on day ll.

Before drug therapy,

the abscess sizes of the SM-1213 treated test group were
not significantly different from the controls; however,
by day 7 the abscesses from the drug treated animals were
significantly smaller than those of the controls.
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Figure 15. Effect of SM-1213 on the course of leg lesions in mice infected intramuscularly with 7 X 106 Candida
albicans cells.
Leg swelling was measured as in Figure 10. Drug
treated groups received 80 ~g SM-1213/kg/day orally in the
drinking water from day 4 to 5 and 400 ~g SM-1213/kg/day for
day 7 to 11. (e) Control, N = 30; (~) SM-1213 treated,
N = 30.
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e.

Leg Lesion Study #5:

Effect of SM-1213 on the Course

of Leg Lesions and Metastasized Fungus in Mice Infected Intramuscularly with 7 X 10 6 Candida albicans
Cells
This study repeated the experimental procedure of
the last study (Leg Lesion Study #4); however, instead of
homogenizing tissues, kidneys, spleens, or abscesses were
cultured.

This method was adopted in order to determine

any presence of Candida in these tissues which may not
have been detected by ordinary homogenization techniques.
Culturing techniques allowed for the determination of
candidal incidence or frequency in these tissues even
when present in small numbers.

Male, CBA/J mice were

infected with 7 X 10 6 Candida cells per mouse intramuscularly; drug therapy was as in Leg Lesion Study #4.
Two sets of animals were sacrificed.

The first

set consisted of ten animals each from the control and
drug groups which had the largest abscesses on day 8.
The spleens, kidneys, and abscesses were removed and
cultured.

No Candida was found in the spleen, while 2

out of 10 control animals and 3 out of 10 drug treated
mice demonstrated Candida present in kidney cultures.
All mice in both test groups contained Candida within
cultured abscesses.
The second set of animals which were sacrificed
consisted of the next ten largest abscesses in each
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experimental group as determined on day 11.

Spleens and

kidneys were not cultured from these animals, but abscesses
were cultured.

As above, all test animals demonstrated

Candida present in abscess cultures (10 out of 10 each
for control and drug treated groups).
Highly significant differences in abscess sizes
were obtained between control and drug treated groups
utilizing this drug regimen, similar to those obtained
in the last leg inoculation study (see Figure 15) .
Uninfected control mice (injected with PBS) had
an average "abscess" size of 0.0 ± 0.01 over the entire
experimental time period (N

= 9).

Total numbers of mice used in this study to determine average abscess sizes were:
treated, N
f.

=

Control, N

= 30; drug

30.

Leg Lesion Study #6:

Effect of SM-1213 on the Course

of Leg Lesions and Metastasized Fungus in Mice Infected Intramuscularly with 1.25 X 10 7 Candida albicans
Cells
A log less Candida than was utilized in Leg Lesion
Study #1 was inoculated into CBA/J mice intramuscularly
(1.25 X 10 7 cfu).
80

~g/kg/day

Mice were treated from day 4 to 5 with

and from day 7 to 11 with 400

~g/kg/day

in

drinking water.
Significant differences were observed on day 5,
6, and 8 in average abscess sizes between control and
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drug treated mice (see Figure 16) .

The overall average

"abscess" size in uninfected control mice was -0.02 ±
0. 02

(N

=

8) .

No differences in frequency of Candida occurrence
in cultured abscesses from control and drug groups were
noted on days of sacrifice (day 11 and 18).

On day 11,

8 out of 8 control and 8 out of 8 drug treated mice had
Candida present within leg abscesses.

On day 18, 9 out

of 9 control and 8 out of 8 drug treated mice had Candida
present in leg lesions.

No significant difference was

observed between control and drug group kidneys cultured
on day 11; however, the difference in frequency of Candida
occurrence in the kidneys by day 18 was significant (see
Table 15) .

It was proposed that drug treatment might

allow for a more rapid clearance of Candida from the
kidney late in infection upon the appearance of specific
or opsonic antibody.
The next experiment to be discussed examines the
long-term evolution of candidal infection in the kidney.
g.

Leg Lesion Study #7:

Effect of SM-1213 on the Quan-

tity of Fungus in Leg Lesions and Kidneys of Mice
Infected Intramuscularly with 1.25 X 10 7 Candida
albicans Cells
The procedure of the last experiment discussed
was repeated in this experiment with the exception of
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Figure 16. Effect of SM-1213 on the course of leg lesions in mice infected intramuscularly with 1.25 X 107
Candida albicans cells.
Leg swelling was measured as in Figure 10. Drug
treated groups received 80 ~g SM-1213/kg/day orally in the
drinking water from day 4 to 5 and 400 ~g SM-1213/kg/day
for day 7 to 11. (e) Control, N = 20; (•) SM-1213 treated,
N = 20.
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Table 15. Leg lesion study #6: Effect of SM-1213 on the frequency of Candida albicans present in kidneys of
intramuscularly infected micea
Treatment
groupb

Frequency of kidneys
containing viable
C.albicans on day 11

Frequency of kidneys
containing viable
C.albicans on day 18

Control

3/8

4/9

SM-1213

5/8

0/8

Significance
levelc

N.S.

p < 0. 05

a)Male, CBA/J mice were injected intramuscularly in the
calf with 1.25 X 10 7 C.albicans cells on day 1. On day 11,
and day 18 post-infection, mice were sacrificed; kidneys
were excised, cultured, and assessed for the presence of
colony forming units on SDA at 37°C.
b)Control mice received no drug; SM-1213 treated mice received 80 ~g SM-1213/kg/day for day 4 to day 5 post-infection and 400 ~g SM-1213/kg/day for day 7 to day 11 orally
in drinking water.
c) N. S. = not significant (P > 0. 05 by x 2 analysis) •
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tissue homogenizations supplementing culturing techniques.
A truly quantitative analysis could then be performed in
addition to a qualitative analysis.

Tissue homogeniza-

tions were performed on the kidneys at day 4, 11, and 18.
In order to insure that the absence of Candida from the
kidneys of drug treated mice on day 18 was not an artifact of homogenization, the kidneys of mice sacrificed
on day 27 were cultured.
Kidney homogenates of control and drug treated
mice showed no significant difference in Candida occurrence at day 4 (prior to treatment) or at day 11 sacrifices.

By day 18, however, significant differences were

observed (see Table 16).

By day 27, culturing techniques

showed that Candida had been cleared from the drug treated
kidneys but not from the control kidneys (see Table 16
and Figure 17).

Frequency of Candida occurrence is shown

in parentheses in Figure 17 and 18.
The course of leg lesion development was much like
that observed for the last experiment; however, abscess
sizes were significantly different between control and
drug treated groups on day 8 and 12 (see Figure 16).
Abscess sizes were not significantly different on days
of sacrifice and the total number of Candida present in
abscesses and the frequency of candidal occurrence were
not significantly different (see Figure 18).

By day 27,

Table 16. Leg lesion study #7: Effect of SM-1213 on the frequency of Candida albicans
present in kidneys of intramuscularly infected micea
Frequency of kidneys containing viable C.albicans
Day 4b

Day 11

Day 18

Day 27

Control

3/4

3/10

7/10

3/11

SM-1213c

4/4

2/10

0/10

0/10

Significance
leveld

N.S.

N.S.

p < 0. 01

N.S.

a)Male, CBA/J mice were injected intramuscularly in the right calf with 1.25 X 10 7
C.albicans cells on day 1. On day 4, 11, 18, and 27 mice were sacrificed; kidneys
were exc1sed and homogenized on day 4, 11, and 18 and assessed for cfu on SDA at
37°C. On day 27, kidneys were excised, minced aseptically, and incubated in SDB for
24 hours at 37°C; cultures were then assessed for the presence or absence of cfu.
b)Day post-infection when 'mice were sacrificed.
c)Control mice received no drug; SM-1213 treated mice received oral drug therapy as
described in Table 15.
d)N.S. = not significant (P > 0.05 by x2 analysis).
ill
\.0

,.......
0
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Figure 17. Effect of SM-1213 on the clearance of Candida albicans from the
kidneys of mice injected intramuscularly with 1.25 X 107 colony forming units.
Mice were sacrificed at day 4, 11, and 18; kidneys were excised, homogenized,
and assessed for cfu by plating serial dilutions of the homogenate on SDA. The ratio
of the number of mice found to have Candida present in the kidneys to the total number of mice sacrificed is represented in parentheses. Control mice received no drug;
drug treated mice received 80 ~g SM-1213/kg/day for day 4 to 5 post-infection and
400 ~g SM-1213/kg/day for day 7 to 11 post-infection orally in drinking water. The
original number of mice in each test group was as follows: (e) Control, N = 40;
(+) SM-1213 treated group, N = 40.
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Figure 18. Effect of SM-1213 on the clearance of Candida albicans from the
abscesses of CBA/J mice infected intramuscularly with 1.25 X 107 colony forming
units.
Mice were sacrificed at day 4, 11, 18, and 27; abscesses were excised, homogenized, and assessed for cfu by plating serial dilutions of the homogenate on SDA.
The ratio of the number of mice found to have Candida present in leg lesions to the
total number of mice sacrificed is represented in parentheses. Control mice received
no drug;drug treated mice received therapy as in Figure 17. The original number of
mice in each test group was as follows: (e) Control, N = 40; C+) SM-1213 treated,
N = 40.
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candida had been cleared from the abscesses.

Abscesses

were homogenized at each sacrifice interval.
The overall average "abscess" size for uninfected
control mice was -0.01 ± 0.02 from day 4 to day 27 (N

=

10) .
Days of sacrifice were pre-determined before the
beginning of this experiment based on the previous study.
In order to further examine the kidney involvement which
occurred in Leg Lesion Study #6, day 11 and day 18 were
once again chosen as days of sacrifice.

Day 4 (prior to

drug treatment) and day 27 were chosen as additional days
of sacrifice.

One difficulty which arose from such pre-

determination was that sacrifices in this experiment
happened to occur on days which did not show significant
differences in abscess sizes between control and drug
treated groups.

For the analysis of kidney involvement,

such sacrifice days were ideal.

However, this interfered

with an attempt to examine the relationship between the
number of Candida within abscesses and abscess size.
It would be of value to determine whether differences in
the number of Candida present within abscesses occurred
on days of significant abscess size differences between
control and drug treated groups.

No significant differ-

ences in Candida number occurred within abscesses which
were not significantly different in size (see Figure 18).
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Since sacrifice days did not include such days of
significance, control and drug treated group abscess sizes
were combined,as were the total average colony forming
units per abscess, to determine the correlation of abscess
size to number of Candida present within abscesses at the
various days of sacrifice; the correlation is strong
(Pearson's r

=

0.81) for those animals sacrificed.

The

correlation between abscess size and total average colony
forming units per abscess is also strong for the entire
population of mice (including those not sacrificed) suggesting that, on the days of sacrifice, the animals sacrificed were representative of the entire study (Pearson's
r

h.

= 0.87).
Leg Lesion Studies #6 and #7:

Combined Data from Leg

Lesion Studies of Mice Infected Intramuscularly with
1.25 X 10 7 Candida albicans Cells
The combined abscess data from Leg Lesion Studies
#6 and #7 are shown in Figure 19.

Significant differences

in abscess sizes are demonstrated early in infection.
Measurements of uninfected control mice are also shown
at the bottom of the graph.
Table 17 delineates the highly significant combined
data obtained on day 18 for the frequency of Candida
present in the kidneys of mice in Study #6 and #7.

No

Candida was detected in uninfected control mice kidneys.

1-'
0

m

Figure 19. Effect of SM-1213 on the course of leg lesions in CBA/J mice infected intramuscularly with 1.25 X 107 Candida albicans cells.
Leg swelling was measured as in Figure 10. Control mice received no drug; drug
treated mice received 80 ~g SM-1213/kg/day for day 4 to 5 post-infection and 400 ~g
SM-1213/kg/day for day 7 to 11 post-infection orally in drinking water. The original
number of mice in each test group was as follows: (e) Control, N = 60; (+) SM-1213
treated, N = 60; and (A) uninfected control (injected with PBS only in the right
leg), N = 18. Data shown is compiled from two experiments.
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Table 17. Leg lesion studies #6 and #7: Effect of SM-1213
on the frequency of Candida albicans present in
kidneys of intramuscularly infected micea
Treatment
group

b

Frequency of kidneys
containing viable
C.albicans on day llc

Frequency of kidneys
containing viable d
c.albicans on day 18

Control

6/18

11/19

SM-1213

7/18

0/18

Uninfected
controle

0/2

0/2

a)Male, CBA/J mice were injected intramuscularly in the calf
with 1.25 X 10 7 C.albicans cells on day 1. On day 11 and
day 18 post-infection, mice were sacrificed; kidneys were
excised, homogenized, and assessed for cfu on SDA at 37°C.
b)Control mice received no drug; SM-1213 treated mice received therapy as described in Table 15.
c)Control mice versus drug treated mice, P > 0.05 by x2 analysis on day 11.
d)Control mice versus drug treated mice, P < 0.001 by x2 analysis on day 18.
e)Uninfected control mice were injected in the calf with PBS
only on day 1.
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Combined data for the frequency of Candida occurrence in abscesses revealed no significant differences
between control and drug treated groups.

On day 11, in

both control and drug groups, 18 of 18 abscesses contained
Candidai on day 18, in the control group 19 of 19 mice had
recoverable Candida, while in the drug group 16 of 18
abscesses contained Candida.

Uninfected control mice had

no recoverable Candida in the kidneys or legs.
The following observations have also been made:
1)

Preliminary histological studies conducted on

day 11 post-infection in this laboratory indicated that
the central area of the leg lesion contained predominantly
polymorphonuclear cell types, while the periphery of the
abscess consisted primarily of mononuclear cell types.
Histological sections were stained with hematoxylin-eosin
(H&E) for cell differentiation analysis.
2)

Wright-Giemsa stained smears of abscess fluid

showed the presence of predominantly polymorphonuclear
cells and cell debris.

In addition, periodic acid-Schiff-

hematoxylin (PASH) stained smears of abscess fluid on day
4 and day 8 of infection showed numerous PAS positive
yeast and pseudohyphal forms of Candida present.

By day

15, the number of Candida present in the fluid was reduced
as compared to day 4 and day 8.
3)

Histological sections of the kidneys on day 11

post-infection from mice infected in the leg muscle with
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1.25 X 10 7 Candida cells showed the presence of polymorphonuclear cells dispersed within the kidneys and both yeast
and pseudohyphal forms of Candida were evident in the
kidney pelvis as detected by PASH staining.

Such a dis-

tribution of Candida is similar to that characterized by
~vinbald

in the chronic type of renal candidiasis (66);

that is, similar to mice surviving intravenous infection
for over ten days.

CHAPTER IV
DISCUSSION
In Vitro Studies
No direct candidacidal or growth inhibitory effect
due to the presence of SM-1213 in the incubation medium
was demonstrated against the yeast or hyphal form of
Candida albicans (Table 1 and 2).

However, SM-1213 was

found to be effective in inhibiting intracellular germ
tube elongation of Candida (Table 3) , as well as in reducing the percentage of viable cells remaining after
phagocytosis (Table 6).

This data suggests that an in-

direct candidacidal effect was exerted by SM-1213 mediated
by the modulation of phagocyte cell processes.
It has been shown that guinea pig peritoneal exudate
cells can suppress the growth of Candida albicans significantly when compared to the unimpeded growth of this
organism in cell-free, tissue culture medium (Table 7).
The ability of these cells to inhibit candidal germ tube
elongation and to kill phagocytized Candida varies, depending upon the type of inducing agent used.

Peritoneal

exudate cells induced by mineral oil were less efficient
than those elicited by glycogen in inhibiting germ tube
elongation (Table 9), as well as in reducing the percentage
111
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of viable Candida remaining after phagocytosis (Table 6).
If these highly significant differences are due to the
cell type produced, this would indicate that the polymorphonuclear cell, which predominates with glycogen induction, is better able to inhibit germ tube elongation
and to reduce the viability of intracellular Candida than
is the oil induced macrophage.

A prediction such as this

must be weighed, however, by the fact that the inducing
agent itself may interfere with the fungicidal abilities
of these cells.

This may be particularly true in the

case of paraffin oil-sated macrophages.

However, other

researchers (2,36,60) have also suggested that the PMN
provides a better defense against candidal invasion than
the macrophage.
In addition, the number of Candida which failed
to produce hyphae intracellularly is significantly greater
in the glycogen induced cells (Table 8).

Apparently there

is a mechanism whereby hyphal formation is inhibited
within responding leukocytes.
The addition of serum to the test medium caused an
inhibition in the average intracellular germ tube length
regardless of the inducing agent used (Table 3).

However,

in the oil induced control group, the germ tube length
was significantly decreased upon the addition of serum.
Oil induced drug treated groups were not significantly
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reduced upon the addition of serum.

Since this phenomenon

is pronounced in the oil induced studies, it is speculated
that SM-1213 treatment may replace an unknown serum factor
important to the macrophage in its ability to inhibit
intracellular germ tube elongation.

Hadden et al (20) ,

working with paraffin oil induced guinea pig macrophages,
determined that SM-1213 was capable of activating macrophages and increasing their phagocytosis of Listeria
monocytogenes in relation to control samples.
SM-1213 at a concentration of 0.12

~g/ml

In addition,

significantly

increased intracellular killing of bacteria without
affecting the viability of the macrophage monolayer.
In the glycogen induced studies, the differences
in average germ tube length upon the addition of serum
were not significantly different in parallel control or
drug treated samples (Table 3).

However, serum did produce

a significant reduction in the number of Candida present
which were able to transform into hyphae (Table B).

In

other words, a significantly greater number of Candida
remained in the yeast form when serum was added.

Thus,

the presence of serum in the incubation medium has been
demonstrated to affect the morphology of the intracellular
Candida.

The retention of Candida in the yeast form may

play an important role in reducing candidal pathogenicity
(37,66).
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The transformation of Candida from the yeast to the
hyphal form has been suggested to be important in the
spread of infection, particularly in the kidney (66).
Winbald (66) observed that yeast cells evaded the immune
system by invading intraluminally into the kidney tubuli
in hyphal form.

The fungi were protected in this environ-

ment and rapidly formed mycelial masses.

Leukocyte

actions which oppose the conversion of Candida from the
yeast to the hyphal form contribute thereby to the prevention of the spread of infection.
Although the fungal hyphae appeared to penetrate
the cell membrane of the peritoneal cells, it is possible
that a thin cell membrane, invisible by standard microscopy, still surrounded the hyphal germ tubes.

This may

account for the appearance of a low viability while germ
tube lengths were relatively long.
SM-1213 significantly enhanced the ability of both
macrophages and neutrophils to inhibit intracellular
growth of Candida (Figure 2, 4, 7).

In addition, the

percentage of viable Candida cells was reduced in those
samples treated with the 0.001

~g/ml

dose (Table 6). An

explanation for the candidacidal effect of SM-1213 treated
phagocytes may lie in the activation of such cells by the
drug.
Normal phagocytic activity is accompanies by activation of oxidative metabolism in phagocytic cells.

A
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result of this activation is the generation of oxidative
intermediates such as superoxides, hydrogen peroxide, and
hydroxyl free radicals (23).

The production of such

"active oxygens" contributes to the destruction of ingested bacteria, but also results in the escape of cytotoxic agents into the surrounding environment.

This can

produce a detrimental effect on surrounding healthy tissue
or on the phagocyte itself.
inflammation.

The result is an increase in

It has been shown that the anti-inflarnrna-

tory effect of superoxide dismutase may be due to the
protection of nearby tissues from damage by the superoxide
radical itself or from its reaction with hydrogen peroxide
and the production of secondary radicals

(55).

Upon phagocytosis of particles, normal polymorphonuclear leukocytes generate chemiluminescence (light
emission) which accompanies the activation of increased
oxidative metabolism (23).

Such chemiluminescence can be

quantitated in a liquid scintillation spectrometer (65).
Studies were conducted by colleagues in this laboratory on glycogen induced guinea pig neutrophils.

Through

the use of chemiluminescence techniques, a more prolonged
generation of microbicidal active oxygens was detected in
0.001 flg Sl\1-1213/ml treated samples than in controls
following phagocytosis of Candida.
However, the activity of Sl\1-1213 appears, in work
being conducted at this time, to be biphasic in its effects
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depending upon the level of drug administered (personal
communication, P. Gordon).

Glycogen elicited peritoneal

neutrophils were examined by scintillation techniques for
chemiluminescent activity representative of superoxide
production upon the addition of 5 X 10 7 heat-killed
Candida cells.

Cells obtained from mice which had been

treated with 16 mg SM-1213/kg in drinking water showed no
increase in extracellular chemiluminescence, while controls increased by 12-fold in the presence of luminal
amplifier.

No differences were detected in intracellular

chemiluminescence between control and drug treated animal
cells.

Thus, it is suggested that the decreased produc-

tion of harmful extracellular oxidative components
associated with decreased extracellular chemiluminescence
produces an anti-inflammatory effect akin to that observed
for superoxide dismutase (25).

At the same time, the

continued intracellular production of active oxygens
allows for the destruction of micro-organisms.

Thus,

high doses (16 mg/kg) of SM-1213 treatment in vivo appear
to be anti-inflammatory, while low doses in vitro (0.001
~g/ml)

prolong chemiluminescence.
Also, Gordon et al (19) found that, in guinea pig

macrophages elicited with paraffin oil and cultured at
37°C, 5% C0 2 for 24 hours in HI-W0 5 /BA2ooo medium, 0.001
~g

SM-1213/ml caused enhanced protein secretion (150%) ,
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increased peroxidase excretion relative to controls, and
increased acid phosphatase activity in macrophage phagesomes.

Colleagues have proposed that SM-1213 may enhance

the microbicidal activity of the myelo-peroxidase or
related microbicidal systems dependent upon superoxide in
these cell types at low levels of drug.
Studies conducted elsewhere have demonstrated the
myelo-peroxidase system to be effectively candidacidal
(32,35).

In addition, in those patients whose immune

systems have an impaired peroxidase system such as those
receiving chemotherapy for metastatic cancer or those
with advanced Hodgkin's disease or acute leukemia (36), as
well as those with chronic granulomatous disease (3,33,34),
while phagocytosis of Candida appeared to be normal,
candidacidal capabilities were significantly reduced.
Although the polymorphonuclear cell has been the primary
focus of these studies, the mouse peritoneal macrophage
has been demonstrated to display a similar anti-microbicidal potential (42).
Thus, while no direct fungicidal or fungistatic
effects were observed against the yeast or hyphal form of
~-

albicans, the effects of SM-1213 in vitro can be ex-

plained as an action upon the phagocytic cells present
and, as indicated above, are probably mediated through
the modulation of intracellular enzymes and their secretion or through other activation products.
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In Vivo Studies
In studies concerning mice injected intravenously
with Candida, it was determined that the interval of drug
administration is highly important to therapeutic effects
(Table 13).

Over a period of 24 days, cumulative mortality

was significantly reduced in mice treated with SM-1213 for
day 3 to day 4 post-infection.

Earlier drug administration

was less effective as the experiments progressed.

It will

be of importance, therefore, to examine the immune mechanisms which are involved at such time intervals, in that
specific enhancement of fungicidal capabilities of SM-1213
may be dependent upon the activation of a particular
population of cell types present after the initiation of
infection.
A suitable model for studying experimentally induced candidiasis was determined to be the mouse leg
lesion model.

A consistent, self-limiting lesion, which

could be easily measured using a Schnelltaster caliper,
was produced by injection of an appropriate inoculum into
the mouse calf muscle.

The enlargement of the abscess

produced served as an indicator of the pathogenesis of the
infection.

Unlike intravenously infected mice which fre-

quently succumb to infection within two weeks, mice survive
intramuscular infection and recover in three to four weeks
allowing for the study of immune responses.

119
Histopathological studies conducted elsewhere (44)
have indicated that such leg lesions are composed of a
large number of yeasts early in infection with a modest
cellular infiltrate during lesion development.

As the

lesion regresses, the number of fungal cells is reduced
and the amount of host cellular infiltrate is increased.
Histologically, the lesions have the characteristics of
an abscess (44).
The mechanisms of protection from candidiasis have
been investigated by Pearsall et al (43), who suggested
that neutrophils, along with a contribution from humoral
immune forces, may be sufficient to limit the infection
in mouse leg lesions.

In vitro studies reported in this

thesis (Table 9) have suggested that, indeed, neutrophils
may be of primary importance.

In addition, the presence

of normal guinea pig serum enhanced inhibition of candidal
germ tube formation (Table 8) , suggesting an influence of
humoral factors [i.e. Candida albicans is so ubiquitous
that even "normal" serum may contain antibodies to this
organism (28) ].
Pearsall et al (43) also demonstrated that passive
transfer of immune serum gave a significant degree of
protection against lesion development in murine candidiasis.

The transfer of resistance by sensitized lymphoid

cells gave negative results, although cutaneous delayed
hypersensitivity was transferred by these cells.
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There is continued controversy over the role of
humoral and cellular immunity in candidal infections.
In studies of experimental systemic candidiasis
in mice intravenously injected with Candida albicans,
complement intact mice survived significantly longer
than complement deficient mice.

It was speculated that

longer survival was due to the earlier and greater mobilization of phagocytic cells {41).

Ray {46) found the

formation of neutrophilic microabscesses in CS-intact
mice infected intraepidermally with Candida.

C5-deficient

mice, however, developed no inflammatory response and
allowed the proliferation and cutaneous invasion of
Candida.

In addition, in vitro studies showed Candida-

induced neutrophil chemotaxis and complement activation.
Giger et al {14) suggested that the acute inflammatory response due to cutaneous infection of mice
with Candida albicans stimulated the production of precipitating antibody and conferred protection against
subsequent intravenous challenge due to predominantly
humoral response.

In addition, Rogers and Balish (51)

demonstrated that, in disseminated candidiasis, renal
histopathology revealed a prominent role for the polymorphonuclear leukocyte, but not for mononuclear cells
in the defense against systemic infection.
The polymorphonuclear cell was also important in
patients with chronic granulomatous disease, where
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susceptibility to candidal infection resulted from an
abnormal function in neutrophils (33).
However, the cellular immune response cannot be
overlooked as an important element in the resistance to
candidal infection.

This was especially evident in those

individuals with chronic mucocutaneous candidiasis who
were able to produce antibody (34) but displayed abnormalities in the cellular immune system (28,31).
Successful treatment of such patients with injections of
transfer factor or transfusions of immunocompetent lymphocytes support a role for thymus-dependent cellular
immunity in protection against candidiasis (28,29).
Controversy has arisen, however, due to evidence
that congenitally athymic mice with deficient thymusdependent cell mediated immunity may actually have a
greater capacity than normal littermates to prevent the
growth of Candida in the kidneys and to clear Candida
from the liver (52) .
Reconciliation between the humoral and cellular
defense theories has been suggested in both cutaneous
and disseminated candidiasis.

Sohnle et al (59) compared

the pathology in chronic and acute candidal lesions in
guinea pigs infected cutaneously with Candida.

Acute

lesions (produced by placing occlusive dressings over
injection sites) were characterized by intense polymorphonuclear infiltration.

In contrast, chronic lesions
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(produced without occlusive dressings) generally presented
an intense dermal infiltrate of mononuclear cells.

How-

ever, such mononuclear infiltration was demonstrated in
previously immunized guinea pigs, while the acute PMN
infiltrate occurred with or without previous exposure to
Candida.

In addition, a mononuclear response could be

acquired by those animals receiving transferred lymphoid
cells and clearance of Candida was postulated to be associated with lymphokine release.

It would be speculated

that, if normal and nude littermates had been previously
exposed to Candida (immunized) , the accompanying cellular
immune protection afforded to the kidney upon antigen
challenge would likely be greater in normal than in nude
littermates.
In systemic candidiasis, Miyake et al (40), in
experiments with intravenously infected normal, nude
(athymic), lethally irradiated, or immunized mice, suggested that non-immune phagocytosis was required early
in infection, while T-cell mediated immunity was required
at late stages in infection in resistance to candidiasis.
In this case, Candida was shown to decline in the liver
of both nude and normal littermates, but increased in
the kidneys of nude mice.

It was suggested that, since

there are fewer fixed macrophages in the kidney than the
liver, an accumulation of macrophages in the kidney
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induced by T-lymphocyte dependent cellular immunity may be
necessary for an effective defense against Candida in this
organ.
In addition, in lethally irradiated normal or nude
AKR mice, in which phagocytic functions were decreased,
increases in cfu were detected in both the liver and the
kidneys from initiation of infection.

Macrophages from

irradiated mice could not as effectively inhibit the
growth of intracellular Candida as could normal macrophages, as demonstrated by the more frequent formation of
mycelia.
Lymphoid cell transfer from AKR mice immunized
intramuscularly with Candida demonstrated a 20% survival
upon intravenous challenge, while few mice receiving nonimmune lymphocytes survived by day 20 (40).

Prior to

day 7, the number of cfu in the kidneys of both groups
of mice were similar.

By day 7, however, mice receiving

immune cells showed a reduction in cfu in the kidney,
although both groups demonstrated similar cfu in the
liver.

Normal or hyperimrnune serum was ineffective in

reducing mortality or liver or kidney involvement.
It appears, therefore, that, while Pearsall (43)
found no lymphoid protection from abscess formation,
cellular immune elements as well as phagocytic elements
are involved in the protection of the kidney.

In
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addition, serum transfer does not afford protection in the
kidney, while transfer of lymphoid cells does (40).
Thus, both the Pl-1N and the macrophage, as well as
other humoral and cellular factors, play important roles
in resistance to candida! infection.

It would be of

interest to examine the effects of immune serum on the
in vitro macrophage culture system in place of normal,
whole serum previously utilized.

Certainly both humoral

and cellular elements are important in the defense against
candidiasis and warrant further investigation.
Mice injected intramuscularly with C. albicans and
subsequently treated with SM-1213 showed a significantly
higher weight gain than controls and a weight gain pattern
more closely resembling uninfected controls (Figure 11) .
This data, along with the lower incidence of Candida
within the spleens of drug treated mice (Table 14),
suggests that SM-1213 treated animals were better able
to clear Candida which had spread systemically.

Perhaps

similar immune mechanisms are involved in the clearance
of Candida from visceral organs in intravenous studies,
since mice receiving a similar drug regimen and dose of
drug as in the original leg lesion study demonstrated the
lowest cumulative mortality after intravenous infection
(Table 13) .
The successive low dose (80
high dose (400

~g/kg)

~g/kg)

followed by

drug regimen has been proven to be
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effective in reducing leg swelling in drug treated mice
as compared to control animals (Figure 12, 15, 16) regardless of the inoculum size tested.

In an experiment where

drug was initially administered by gavage (Figure 13),
followed by drinking water administration of SM-1213,
significant differences in abscess sizes were also observed between control and drug treated mice.

Gavage

therapy was discontinued due to the revelation that gavage
therapy could cause alterations of immune responses as a
result of the additional stress received during this
procedure and due to the discovered rapid clearance of
SM-1213 in the urine when administration was limited to
a single, heavy dosage per day rather than small doses
three to four times per day as received in drinking water
therapy (personal communication, P. Gordon and J. Majde).
While low doses of drug (80

~g/kg)

given early in

infection enhanced clearance of Candida from the spleen
after leg inoculation (Table 14) and reduced mortality
in intravenous studies (Table 13), larger doses (400
~g/kg)

effected a reduction in leg swelling relative to

controls (Figure 12, 15, 16), while generating neither
an increase nor a decrease in the number of recoverable
Candida obtained within the abscesses (Figure 18).

This

suggests that larger doses of SM-1213 are anti-inflammatory, since smaller abscesses apparently contained a
similar number of Candida organisms.
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This has been borne out subsequently by experiments
conducted by colleagues in this laboratory.

In studies

employing peritoneal exudate cells from SM-1213 treated
mice, a biphasic dose response was noted.

Twenty-four

hours prior to cell harvest, either 10 7 Candida cells or
20 mg of glycogen were injected into the peritoneum.
mice receiving 40 to 80

~g

In

SM-1213/kg doses for short

duration (2 days) , a dose dependent increase in total
leukocyte count and polymorphonuclear leukotaxis into the
peritoneum was revealed.
~g

However, in mice receiving 800

SM-1213/kg doses or greater for longer intervals (3

to 60 days) , a dose dependent decrease occurred in PMN
and leukocyte migration into the peritoneum.

However,

such a decrease was associated with an increase in microbicidal abilities in the responding cells.
Upon reinoculation of mice in the contralateral
leg (Figure 14) , significant differences were obtained
early after Candida injection between previously drug
treated and control CBA/J mice.

The appearance of smaller

abscesses in the SM-1213 treated mice may be explained as
the consequence of an enhanced immunity, since no further
drug therapy was administered during the reinoculation
interval.

According to the work of Pearsall and Lagunoff

(43), such protection would be indicative of an enhanced
humoral response.

However, these authors do not exclude
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the possible contribution of immune lymphocytes in the
resolution of abscesses based on the available evidence.
Further studies conducted by Pearsall et al (45) have
demonstrated a direct anti-fungal activity of lymphokine
preparations in vitro and suggest that the decrease in
fungi in the leg lesions after the second week of the
primary infection in vivo may be partly due to the contribution of lymphocytes present in the lesions.
Little or no systemic spreading of Candida occurred
in those studies where 7 X 10 6 Candida cells were injected
intramuscularly.

For the examination of immune mechanisms

in convalescing mice, such a limited, localized lesion
should prove ideal.

In addition, since this inoculum

gives reproducibly significant differences in abscess
size between control and drug treated mice (Figure 15) ,
future studies examining the relationship of abscess size
to candidal cfu per abscess should utilize this inoculum.
While abscess sizes were reduced in drug treated
mice inoculated with 1.25 X 10 7 C. albicans (Figure 16),
no reduction in Candida count was observed on sacrifice
days as determined by tissue homogenization procedures.
However, no sacrifice days occurred on days of significant
abscess size differences.

It is unlikely that an erratic

clearance of Candida would occur within the abscesses and
it is more probable that a steady, progressive clearance
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would occur as indicated in Figure 18.

The frequency of

candidal occurrence, as well as the total number of recoverable Candida,was similar in both the control and
drug treated groups on days of sacrifice.
Apparently, on days where no significant difference
in abscess sizes was observed, a direct correlation existed between abscess size and the number of Candida cfu
per abscess.

However, few data points were used to deter-

mine this correlation and a greater number of points
should be obtained for analysis before this relationship
can be stated unequivocally.

Also, points occurring

where significant differences are present between control
and drug treated abscess sizes must be analyzed in the
future.
A strikingly significant difference in the frequency of Candida obtained from the kidneys of mice in
these studies was obtained, whether culturing or tissue
homogenization techniques were employed.

Such differences

are related to an enhanced clearance of Candida from the
kidneys of drug treated mice, since no difference in
candidal frequency was observed until day 18 postinfection (Table 16).

In addition, the total number of

Candida present, as well as the frequency of occurrence,
was greater in the kidneys of control mice (Figure 17).
Current studies by colleagues in this laboratory
have suggested a role for SM-1213 as a mitogenic agent.
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Peritoneal exudate cells from mice treated with SM-1213
have shown a significantly greater uptake of radioactive
thymidine relative to controls, especially in the presence
of phagocytic activity.
The effect of SM-1213 on the reduction of extracellular active oxygen production suggests an explanation
for its ability to promote mitogenicity.

The production

of active oxygens by PMN leukocytes normally accompanies
the process of phagocytosis as a result of an increase in
the oxidative metabolism of these cells upon contact with
a stimulus such as Candida albicans or zymosan (65).

In

mouse peritoneal cells which demonstrate chemiluminescence
accompanying the phagocytosis of heat-killed Candida,
prior in vivo SM-1213 treatment served to protect peritoneal phagocytes and lymphocytes from damage by reducing
extracellular active oxygens in vitro.
Damage to lymphocytes and phagocytes by active
oxygens has been discussed by other researchers (8,54).
Damage to fixed tissue also accompanies the production
of active oxygens by stimulated neutrophils (53) and by
active oxygens associated with an arthritic response (25).
It may be that SM-1213 protects both fixed tissues
and lymphocytes participating in an inflammatory response
indirectly by reducing the release of active oxygens from
neighboring polymorphonuclear leukocytes.

Lymphocyte
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mitogenicity could therefore be preserved in these protected cells due to the indirect influence of SM-1213.
Thus, SM-1213 treatment reduces lymphoid cell damage at
the site of inflammation in vivo, thereby preserving
lymphocyte mitogenicity in vitro and therefore presumably
in vivo.

Such preservation could allow for the enhanced

clearance of Candida from the kidney of mice treated with
SM-1213, as demonstrated in Figure 17 and Table 17.
In light of the possible mitogenic effect SM-1213
may exert upon lymphocytic cells, as well as its ability
to activate macrophages in tissue culture, a cellular
role is also indicated in the enhanced clearance of
Candida from the kidney in SM-1213 treated mice.

Although

histological sections of the kidney from mice injected
with 1.25 X 10 7 Candida cells intramuscularly showed
predominantly PMN leukocytes present, no sections were
made after the second week of infection.

Therefore, if

a greater accumulation of mononuclear cells were to occur
after the second week of infection [as in the abscess
model proposed by Pearsall (44) ], such an accumulation
may not have been detected.

However, a small number of

mononuclear cells were present in the kidney and at the
site of abscess formation as observed by this researcher
and by others (44).
Cellular as well as humoral factors have also been
suggested for the clearance of systemically spread Candida
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from the kidneys after intravenous injection.

Corbel and

Eades (9) examined the relative susceptibility of CBA and
New Zealand Black (NZB) mice, a strain known to spontaneously develop deficiencies in cell-mediated immune
function (24) to systemic candidiasis.

Six weeks after

intravenous injection of Candida, CBA mice developed predominantly mononuclear reactions with lymphocytes and
plasma cells readily apparent in the kidneys, while NZB
mice developed progressive, disseminated infection with
essentially non-specific PMN leukocytes and mononuclear
phagocytes but no lymphocytes present in the kidneys.
The greater susceptibility of NZB mice to Candida spread
was suggested to be due to reduced ability to mount a
specific T-lymphocyte dependent response to the fungus.
Rogers and Balish (51) have suggested that humoral
factors may be involved in the clearance of Candida from
the kidneys of mice.

Histological studies conducted by

these authors have indicated that, for the first 21 days
after infection, the predominant cell type was the PMN
leukocyte.

Few PMN's were observed at day 7 post-

infection; by day 14, however, a dramatic increase in the
number of PMN's present occurred with the appearance of
a few monocytes and almost no lymphocytes.

By day 21,

PMN's still predominated, and a small number of monocytes
and lymphocytes were present.

It was suggested that, if
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the PHN leukocyte was responsible for the eventual clearance of Candida from the kidney, the possibility of
antibody-mediated protection by antibody plus complement
mediated chemotaxis of PMN cells would be consistent with
the observed data.

However, the possibility of direct

lymphokine mediated Candida clearance (45,56), as well as
the influence of thymus derived cells upon the function
of the

P~~

itself (7,49), was also suggested.

Winbald

(66) and Hurley and Winner (26) also suggested a role for
the PMN leukocyte early in murine kidney infection (prior
to day 6 post-infection) .
Finally, in histological studies conducted by
Miyake et al (40), irradiated mice, with decreased phagocytic function, exhibited large numbers of mycelial
Candida in kidney sections with little cellular infiltrate
present two days post-intravenous infection.

Normal or

nude mice with unimpaired phagocytic function showed
little Candida present in the kidneys.

Non-immune phago-

cytosis is therefore important early in infection.
By 20 days post-infection, normal mice exhibited
a large cellular infiltrate with an accumulation of macrophages and little or no Candida was observed.

In nude

mice, however, little cellular infiltrate was present,
while large numbers of Candida occurred in the kidney
pelvis.
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Thus, non-immune phagocytosis confines Candida
early in infection, while, at day 20 with the contributions of cellular and humoral elements, Candida can be
cleared from the kidney.

SUMMARY
SM-1213, a substituted monosaccharide with irnrnunomodulatory activity, was examined for its effects on
pathogenesis and immunity in experimentally induced
Candida albicans infections in laboratory animals and for
its effects on the intracellular germ tube elongation and
viability of Candida in tissue culture.
In vitro studies utilizing non-immune guinea pig
pe~itoneal

Pi~

and macrophages indicated that the glycogen

induced PMN leukocyte was better able to suppress the
intracellular germ tube elongation of Candida albicans
than was the oil induced macrophage.

The addition of

whole, normal guinea pig serum to the tissue cultures
reduced the average germ tube length of the oil induced
control sample significantly.

The drug treated samples

were not significantly affected by the addition of serum.
It was speculated that SM-1213 was mimicking a serum
factor important to the macrophage for its inhibition of
germ tube elongation.

In glycogen induced celis, the

addition of serum to the tissue culture medium increased
the number of Candida remaining in the yeast form.

This

factor may play an important role in limiting the spread
of Candida attributed to the formation of invasive, hyphal
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forms.

The addition of SM-1213 reduced both the average

germ tube length of intracellular Candida and the percentage of viable cells remaining after phagocytosis.
This effect was particularly significant at the 0.001
~g/ml

dose level.
In order to determine the effects of SM-1213 on

parameters of host defense against systemic candidal
infection, experiments were conducted on mice infected
intravenously with Candida albicans.

In systemically

infected Ha/ICR mice, SM-1213 could reduce cumulative
mortality when administered for specific 24-hour intervals
in the drinking water.

A dosage of 80

~g/kg/day

was

highly effective when administered from day 3 to 4 in
infection and was less effective when given earlier.
This suggests that immune mechanisms may be most sensitive
to regulation three days post-infection and that treatment
prior to infection is unnecessary, unlike other immunepotentiating drugs.
An injection of 1.25 X 10 7 Candida albicans cells
into the leg muscle of CBA/J mice gave a consistent, selflimiting lesion which could be easily measured and which
served as an indicator of the pathogenesis of infection.
Histopathology conducted here and by others has indicated
that resistance to infection involves the early mobilization of non-immune phagocytes in both the kidney and the
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abscess.

The predominant cell produced early after in-

fection was the PMN, which has been shown in vitro to be
an effective inhibitor of candidal spread.
Under proper drug protocols, consisting of successive doses of low (80
(400

~g/kg/day)

~g/kg/day)

followed by high dose

treatment, significant differences in

abscess sizes between the drug and control groups were
observed early after infection (day 5 to 8).

If non-

immune phagocytes are the primary cell type present early
in infection, SM-1213 can reduce inflammation produced by
such cells when administered in this manner.

The number

of Candida recovered from the abscesses of drug and control groups were not significantly different on days of
sacrifice.

Therefore, while SM-1213 reduces inflammation,

it does so without impairing net fungicidal capabilities
of the responding leukocytes.
The possible anti-inflammatory effect of SM-1213
may serve to protect proto-immune cells from inflammatory
injury so that, when cellular factors are mobilized later
in infection, fungal clearance is more rapid and complete.
Humoral factors may also play an important role in kidney
as well as abscess pathology.

Protection of cutaneously

immunized mice upon subsequent intravenous challenge has
been attributed to a predominantly humoral response.
Antibody-mediated transfer of immunity against leg lesion
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development has been demonstrated by others and a possible
direct candidacidal effect due to lymphokine production
has been proposed.

The mechanism of Candida clearance

from the kidneys of systemically infected mice has been
the subject of much controversy; however, early mobilization of non-immune phagocytes followed by subsequent T-cell
mediated immunity appear to be important factors.
When larger doses of Candida were used as leg
inocula (1.25 X 10 8 ) , the greatest differences in abscess
sizes between drug and control groups occurred late in
infection.

If clearance of Candida from the abscesses

late in infection is due to cellular elements (lymphokine
production in particular), SM-1213 could also reduce
inflammation caused by this system late in infection.
Upon reinoculation of recovered mice, animals which had
been treated with SM-1213 during the course of the primary
infection produced smaller abscesses than did the control
group.

Therefore, SM-1213 enhanced the development of

immunity to a second infection without additional drug
treatment.

In addition, the more complete clearance of

Candida from the spleen in drug treated mice also suggests
an enhancement of immune mechanisms without an enhancement
of inflammation.

The mitogenicity of SM-1213 would sup-

port an opsonin or cellular immune promoted enhanced
clearance of Candida from the kidneys.
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Finally, when an inoculum of 7 X 10 6 Candida cells
was injected intramuscularly into mice, a more localized,
limited lesion occurred with little or no systemic
spreading of Candida.

This suggested that, if an inoc-

ulum was small, non-immune phagocytosis was able to limit
the spread of Candida early in infection more efficiently
than when larger inocula were used.

Abscesses produced

as a result of the lower inoculum were smaller and regressed earlier after infection.

Highly significant

differences were observed in abscess sizes between control and drug treated groups when successive low and high
drug doses were administered.
In conclusion, the above studies, along with those
of others, have demonstrated that SM-1213 can enhance the
host's ability to produce an anti-candidal effect which
may be facilitated by an indirect, anti-inflammatory
action.
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